<html lang="en" class="pb-page js" data-request-id="94d6530837aaf198-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6530837aaf198-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/MMFx-Bm9JrRn6P8xwdVmP0EU4f-94Gbki_L_3TZ-iVllwdDJ38_fVRQeuqKQvX8CDdgxUbRzcH5bBfzFcWKchw=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Remdesivir for the Treatment of Covid-19 — Final Report | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6530837aaf198-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.37070443621521665"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Infectious Disease">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Viral Infections|Coronavirus|Infectious Disease General|Global Health|Influenza"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2007764","title":"Remdesivir for the Treatment of Covid-19 — Final Report","category":"Research","type":"Original Article","topics":"Viral Infections|Coronavirus|Infectious Disease General|Global Health|Influenza","specialties":"Infectious Disease","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2020-11-05T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Infectious Disease\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Viral Infections|Coronavirus|Infectious Disease General|Global Health|Influenza\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2007764","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":{"type":"Quick Take","title":"Remdesivir for the Treatment of Covid-19 — Final Report","doi":"10.1056/NEJMdo005866","issueDate":"2020-11-05T00:00Z","age":"6Months-1990","isFree":"y","topics":"Viral Infections|Infectious Disease General|Global Health|Influenza","viewType":"Full","specialties":"Infectious Disease"}};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6530837aaf198-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Remdesivir for the Treatment of Covid-19 — Final Report"><meta name="dc.Creator" content="John H. Beigel"><meta name="dc.Creator" content="Kay M. Tomashek"><meta name="dc.Creator" content="Lori E. Dodd"><meta name="dc.Creator" content="Aneesh K. Mehta"><meta name="dc.Creator" content="Barry S. Zingman"><meta name="dc.Creator" content="Andre C. Kalil"><meta name="dc.Creator" content="Elizabeth Hohmann"><meta name="dc.Creator" content="Helen Y. Chu"><meta name="dc.Creator" content="Annie Luetkemeyer"><meta name="dc.Creator" content="Susan Kline"><meta name="dc.Creator" content="Diego Lopez de Castilla"><meta name="dc.Creator" content="Robert W. Finberg"><meta name="dc.Creator" content="Kerry Dierberg"><meta name="dc.Creator" content="Victor Tapson"><meta name="dc.Creator" content="Lanny Hsieh"><meta name="dc.Creator" content="Thomas F. Patterson"><meta name="dc.Creator" content="Roger Paredes"><meta name="dc.Creator" content="Daniel A. Sweeney"><meta name="dc.Creator" content="William R. Short"><meta name="dc.Creator" content="Giota Touloumi"><meta name="dc.Creator" content="David Chien Lye"><meta name="dc.Creator" content="Norio Ohmagari"><meta name="dc.Creator" content="Myoung-don Oh"><meta name="dc.Creator" content="Guillermo M. Ruiz-Palacios"><meta name="dc.Creator" content="Thomas Benfield"><meta name="dc.Creator" content="Gerd Fätkenheuer"><meta name="dc.Creator" content="Mark G. Kortepeter"><meta name="dc.Creator" content="Robert L. Atmar"><meta name="dc.Creator" content="C. Buddy Creech"><meta name="dc.Creator" content="Jens Lundgren"><meta name="dc.Creator" content="Abdel G. Babiker"><meta name="dc.Creator" content="Sarah Pett"><meta name="dc.Creator" content="James D. Neaton"><meta name="dc.Creator" content="Timothy H. Burgess"><meta name="dc.Creator" content="Tyler Bonnett"><meta name="dc.Creator" content="Michelle Green"><meta name="dc.Creator" content="Mat Makowski"><meta name="dc.Creator" content="Anu Osinusi"><meta name="dc.Creator" content="Seema Nayak"><meta name="dc.Creator" content="H. Clifford Lane"><meta name="dc.Description" content="Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious.We conducted a double-bli..."><meta name="Description" content="Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious.We conducted a double-bli..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2020-11-05"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2007764"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202011053831909"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMoa2015301"><meta name="dc.Relation" content="10.1056/NEJMe2018715"><meta name="dc.Relation" content="YXQYoa2007764"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2020 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2007764">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2007764">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2007764">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Remdesivir for the Treatment of Covid-19 — Final Report | NEJM">
        <meta property="og:title" content="Remdesivir for the Treatment of Covid-19 — Final Report | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2007764">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/ecb4d94c-8b4d-4431-b1a3-b3f8e6229f2a/nejmoa2007764_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/ecb4d94c-8b4d-4431-b1a3-b3f8e6229f2a/nejmoa2007764_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Although several therapeutic agents have been evaluated for the treatment of coronavirus
disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious.
We conducted a double-bl...">
        <meta name="twitter:description" content="Although several therapeutic agents have been evaluated for the treatment of coronavirus
disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious.
We conducted a double-bl...">
    


    
    
        <meta property="og:image:width" content="2345">
    


    
    
        <meta property="og:image:height" content="3438">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="citation_fulltext_world_readable" content="">
    <meta name="publication_doi" content="10.1056/NEJMoa2007764">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2007764">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:doi\:10.1056/nejm_2020.383.issue-19;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;article:article:doi\:10.1056/NEJMoa2007764;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2007764" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2007764" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2007764" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2007764" class="inputDoi"><input type="hidden" value="J.H. Beigel and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2020;383:1813-1826" class="inputCitation"><input type="hidden" value="05-22-2020" class="inputEPubDate"><input type="hidden" value="November 2020" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Remdesivir for the Treatment of Covid-19 — Final Report" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6530837aaf198-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li><div style="clear: both;"></div></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Remdesivir for the Treatment of Covid-19 — Final Report</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">John H.</span> <span property="familyName">Beigel</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-4879-4941" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-4879-4941</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kay M.</span> <span property="familyName">Tomashek</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Lori E.</span> <span property="familyName">Dodd</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Aneesh K.</span> <span property="familyName">Mehta</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Barry S.</span> <span property="familyName">Zingman</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Andre C.</span> <span property="familyName">Kalil</span>, <span property="honorificSuffix">M.D., M.P.H.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-6489-6294" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-6489-6294</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Elizabeth</span> <span property="familyName">Hohmann</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+33</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Helen Y.</span> <span property="familyName">Chu</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Annie</span> <span property="familyName">Luetkemeyer</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Susan</span> <span property="familyName">Kline</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Diego</span> <span property="familyName">Lopez de Castilla</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Robert W.</span> <span property="familyName">Finberg</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kerry</span> <span property="familyName">Dierberg</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Victor</span> <span property="familyName">Tapson</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Lanny</span> <span property="familyName">Hsieh</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Thomas F.</span> <span property="familyName">Patterson</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Roger</span> <span property="familyName">Paredes</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Daniel A.</span> <span property="familyName">Sweeney</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">William R.</span> <span property="familyName">Short</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Giota</span> <span property="familyName">Touloumi</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">David Chien</span> <span property="familyName">Lye</span>, <span property="honorificSuffix">M.B., B.S.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-0324-0205" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-0324-0205</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Norio</span> <span property="familyName">Ohmagari</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Myoung-don</span> <span property="familyName">Oh</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Guillermo M.</span> <span property="familyName">Ruiz-Palacios</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Thomas</span> <span property="familyName">Benfield</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Gerd</span> <span property="familyName">Fätkenheuer</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mark G.</span> <span property="familyName">Kortepeter</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Robert L.</span> <span property="familyName">Atmar</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">C. Buddy</span> <span property="familyName">Creech</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jens</span> <span property="familyName">Lundgren</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Abdel G.</span> <span property="familyName">Babiker</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sarah</span> <span property="familyName">Pett</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">James D.</span> <span property="familyName">Neaton</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Timothy H.</span> <span property="familyName">Burgess</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Tyler</span> <span property="familyName">Bonnett</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Michelle</span> <span property="familyName">Green</span>, <span property="honorificSuffix">M.P.H., M.B.A.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mat</span> <span property="familyName">Makowski</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Anu</span> <span property="familyName">Osinusi</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Seema</span> <span property="familyName">Nayak</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">H. Clifford</span> <span property="familyName">Lane</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-9509-1045" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-9509-1045</a></span></span>, for <span property="author" typeof="Person" role="listitem">the ACTT-1 Study Group Members<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-33</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">May 22, 2020</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2020<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">383</span></span>:<span property="pageStart">1813</span>-<span property="pageEnd">1826</span></div><div class="doi">DOI: 10.1056/NEJMoa2007764</div><div class="core-enumeration"><a href="/toc/nejm/383/19"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">383</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">19</span></span></a></div><div><a href="#tab-information">Copyright © 2020</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DJohn%2BH.%2BBeigel%252C%2BKay%2BM.%2BTomashek%252C%2BLori%2BE.%2BDodd%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D19%26contentID%3D10.1056%252FNEJMoa2007764%26title%3DRemdesivir%2Bfor%2Bthe%2BTreatment%2Bof%2BCovid-19%2B%25E2%2580%2594%2BFinal%2BReport%26publicationDate%3D11%252F05%252F2020" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2007764" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DJohn%2BH.%2BBeigel%252C%2BKay%2BM.%2BTomashek%252C%2BLori%2BE.%2BDodd%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D19%26contentID%3D10.1056%252FNEJMoa2007764%26title%3DRemdesivir%2Bfor%2Bthe%2BTreatment%2Bof%2BCovid-19%2B%25E2%2580%2594%2BFinal%2BReport%26publicationDate%3D11%252F05%252F2020" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/c17c7033-a7af-419a-a5ee-59689a085504/nejmoa2007764.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2007764.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2007764" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2007764" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2007764.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo). Those who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P&lt;0.001, by a log-rank test). <a id="exam-tint-three-c"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="three-c">In an analysis that used a proportional-odds model with an eight-category ordinal scale, the patients who received remdesivir were found to be more likely than those who received placebo to have clinical improvement at day 15 (odds ratio, 1.5; 95% CI, 1.2 to 1.9, after adjustment for actual disease severity).</span> The Kaplan–Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). Serious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%) and in 163 of the 516 patients who received placebo (31.6%).</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT04280705" target="_blank">NCT04280705</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo005866/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/59a50baa-c3c4-45c9-937e-0216aaa1738f/media/NEJMdo005866_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo005866/full/" class="ng-do-media_item-title-link">Remdesivir for the Treatment of Covid-19 — Final Report</a>
            </h6>
            <div class="ng-do-media_item-duration">1m 45s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in December 2019 as the cause of a respiratory illness designated coronavirus disease 2019, or Covid-19.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1" href-manipulated="true" aria-label="Reference 1">1</a></sup> Several therapeutic agents have been evaluated for the treatment of Covid-19, but no antiviral agents have yet been shown to be efficacious.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2 r3" id="body-ref-r3" href-manipulated="true">2,3</a></sup> Since the publication of our preliminary report, dexamethasone has been shown to decrease mortality (25.7% in the usual care group vs. 22.9% in the dexamethasone group; P&lt;0.001), with the largest benefit seen among patients receiving invasive mechanical ventilation.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4-1" href-manipulated="true" aria-label="Reference 4">4</a></sup></div><div role="paragraph">Remdesivir (GS-5734), an inhibitor of the viral RNA-dependent, RNA polymerase with in vitro inhibitory activity against SARS-CoV-1 and the Middle East respiratory syndrome (MERS-CoV),<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r6 r7 r8" id="body-ref-r8" href-manipulated="true">5-8</a></sup> was identified early as a promising therapeutic candidate for Covid-19 because of its ability to inhibit SARS-CoV-2 in vitro.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9" href-manipulated="true" aria-label="Reference 9">9</a></sup> In addition, in nonhuman primate studies, remdesivir initiated 12 hours after inoculation with MERS-CoV<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r11" id="body-ref-r11" href-manipulated="true">10,11</a></sup> reduced lung virus levels and lung damage.</div><div role="paragraph">To evaluate the clinical efficacy and safety of putative investigational therapeutic agents among hospitalized adults with laboratory-confirmed Covid-19, we designed an adaptive platform trial to rapidly conduct a series of phase 3, randomized, double-blind, placebo-controlled trials. Here, we describe the first stage of the Adaptive Covid-19 Treatment Trial (ACTT-1), in which we evaluated treatment with remdesivir as compared with placebo. The results presented here represent an update to a preliminary report after complete follow-up.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Design</h3><div role="paragraph">Enrollment for ACTT-1 began on February 21, 2020, and ended on April 19, 2020. There were 60 trial sites and 13 subsites in the United States (45 sites), Denmark (8), the United Kingdom (5), Greece (4), Germany (3), Korea (2), Mexico (2), Spain (2), Japan (1), and Singapore (1). Eligible patients were randomly assigned in a 1:1 ratio to receive either remdesivir or placebo. Randomization was stratified by study site and disease severity at enrollment. Patients were considered to have severe disease if they required mechanical ventilation, if they required supplemental oxygen, if the oxygen saturation as measured by pulse oximetry (Sp<span data-style="small-caps">o</span><sub>2</sub>) was 94% or lower while they were breathing ambient air, or if they had tachypnea (respiratory rate ≥24 breaths per minute). Remdesivir was administered intravenously as a 200-mg loading dose on day 1, followed by a 100-mg maintenance dose administered daily on days 2 through 10 or until hospital discharge or death. A matching placebo was administered according to the same schedule and in the same volume as the active drug. A normal saline placebo was used at the European sites and at some non-European sites owing to a shortage of matching placebo; for these sites, the remdesivir and placebo infusions were masked with an opaque bag and tubing covers to maintain blinding. All patients received supportive care according to the standard of care for the trial site hospital. If a hospital had a written policy or guideline for use of other treatments for Covid-19, patients could receive those treatments. In the absence of a written policy or guideline, other experimental treatment or off-label use of marketed medications intended as specific treatment for Covid-19 were prohibited from day 1 through day 29 (though such medications could have been used before enrollment in this trial).</div><div role="paragraph">The trial protocol was approved by the institutional review board at each site (or by a centralized institutional review board as applicable) and was overseen by an independent data and safety monitoring board. Written informed consent (or consent by other institutional review board-approved process) was obtained from each patient or from the patient’s legally authorized representative if the patient was unable to provide consent. Full details of the trial design, conduct, oversight, and analyses can be found in the <a href="#ap4">protocol</a> and statistical analysis plan (available with the full text of this article at NEJM.org).</div></section><section id="sec-1-2"><h3>Procedures</h3><div role="paragraph">Patients were assessed daily during their hospitalization, from day 1 through day 29. Patients’ clinical status was assessed on an eight-category ordinal scale (defined below) and the National Early Warning Score (which includes six physiological measures; total scores range from 0 to 20, with higher scores indicating greater clinical risk) were recorded each day.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12 r13" id="body-ref-r13" href-manipulated="true">12,13</a></sup> All serious adverse events and grade 3 or 4 adverse events that represented an increase in severity from day 1 and any grade 2 or higher suspected drug-related hypersensitivity reactions were recorded. (See the full description of trial procedures in the <a href="#ap1">Supplementary Appendix</a>, available at NEJM.org.)</div></section><section id="sec-1-3"><h3>Outcomes</h3><div role="paragraph">The primary outcome was the time to recovery, defined as the first day, during the 28 days after enrollment, on which a patient met the criteria for category 1, 2, or 3 on the eight-category ordinal scale. The categories are as follows: 1, not hospitalized and no limitations of activities; 2, not hospitalized, with limitation of activities, home oxygen requirement, or both; 3, hospitalized, not requiring supplemental oxygen and no longer requiring ongoing medical care (used if hospitalization was extended for infection-control or other nonmedical reasons); 4, hospitalized, not requiring supplemental oxygen but requiring ongoing medical care (related to Covid-19 or to other medical conditions); 5, hospitalized, requiring any supplemental oxygen; 6, hospitalized, requiring noninvasive ventilation or use of high-flow oxygen devices; 7, hospitalized, receiving invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); and 8, death.</div><div role="paragraph">The key secondary outcome was clinical status at day 15, as assessed on the ordinal scale. Other secondary outcomes included the time to improvement of one category and of two categories from the baseline ordinal score; clinical status as assessed on the ordinal scale at days 3, 5, 8, 11, 15, 22, and 29; mean change in status on the ordinal scale from day 1 to days 3, 5, 8, 11, 15, 22, and 29; time to discharge or National Early Warning Score of 2 or less (maintained for 24 hours), whichever occurred first; change in the National Early Warning Score from day 1 to days 3, 5, 8, 11, 15, 22, and 29; number of days with supplemental oxygen, with noninvasive ventilation or high-flow oxygen, and with invasive ventilation or ECMO up to day 29 (if these were being used at baseline); the incidence and duration of new oxygen use, of noninvasive ventilation or high-flow oxygen, and of invasive ventilation or ECMO; number of days of hospitalization up to day 29; and mortality at 14 and 28 days after enrollment. Secondary safety outcome measures included grade 3 and 4 adverse events and serious adverse events that occurred during the trial, discontinuation or temporary suspension of infusions, and changes in assessed laboratory values over time.</div></section><section id="sec-1-4"><h3>Statistical Analysis</h3><div role="paragraph">The primary analysis was a stratified log-rank test of time to recovery with remdesivir as compared with placebo, with stratification by disease severity (the actual severity at baseline). (See the <a href="#ap1">Supplementary Appendix</a> for more information about the planned statistical analysis.) For time-to-recovery and time-to-improvement analyses, data for patients who did not recover and data for patients who died were censored at day 29.</div><div role="paragraph">Prespecified subgroups in these analyses were defined according to sex, baseline disease severity (according to stratification criteria and on the basis of the ordinal scale), age (18 to 39 years, 40 to 64 years, or ≥65 years), race, ethnic group, duration of symptoms before randomization (measured as ≤10 days or &gt;10 days, in quartiles, and as the median), site location, and presence of coexisting conditions. (See the <a href="#ap4">protocol</a> for more information about the trial methods.) To assess the effect of disease severity on treatment benefit (recovery and mortality), post hoc analyses evaluated interactions of efficacy with baseline ordinal score (as a continuous variable).</div><div role="paragraph"><a id="exam-tint-one-c"></a><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="one-c">The primary outcome was initially a comparison of clinical status at day 15 on the eight-category ordinal scale. However, the primary outcome was changed to a comparison of time to recovery by day 29 in response to evolving information, external to the trial, indicating that Covid-19 may have a more protracted course than previously anticipated.</span> The change was proposed on March 22, 2020 (after 72 patients had been enrolled), by trial statisticians who were unaware of treatment assignments and had no knowledge of outcome data. The amendment was finalized on April 2, 2020, and the initial primary outcome was retained as the key secondary outcome.</div><div role="paragraph">On April 27, 2020, the data and safety monitoring board reviewed efficacy results. Although this review was originally planned as an interim analysis, because of the rapid pace of enrollment, the review occurred after completion of enrollment while follow-up was still ongoing. At the time of the data and safety monitoring board report, which was based on data cutoff date of April 22, 2020, a total of 482 recoveries (exceeding the estimated number of recoveries needed for the trial) and 81 deaths had been entered in the database. At that time, the data and safety monitoring board recommended that the preliminary primary analysis report and mortality data from the closed safety report be provided to trial team members from the National Institute of Allergy and Infectious Diseases (NIAID). These results were subsequently made public. The treating physician could request to be made aware of the treatment assignment of patients who had not completed day 29 if clinically indicated (e.g., because of worsening clinical status), and patients originally in the placebo group could be given remdesivir.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients</h3><div role="paragraph">Of the 1114 patients who were assessed for eligibility, 1062 underwent randomization; 541 were assigned to the remdesivir group and 521 to the placebo group (intention-to-treat population) (<a href="#f1">Figure 1</a>); 159 (15.0%) were categorized as having mild-to-moderate disease, and 903 (85.0%) were in the severe disease stratum. Of those assigned to receive remdesivir, 531 patients (98.2%) received the treatment as assigned. Fifty-two patients had remdesivir treatment discontinued before day 10 because of an adverse event or a serious adverse event other than death and 10 withdrew consent. Of those assigned to receive placebo, 517 patients (99.2%) received placebo as assigned. Seventy patients discontinued placebo before day 10 because of an adverse event or a serious adverse event other than death and 14 withdrew consent.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2007764_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2007764_f1.jpg"><img src="/cms/10.1056/NEJMoa2007764/asset/ecb4d94c-8b4d-4431-b1a3-b3f8e6229f2a/assets/images/large/nejmoa2007764_f1.jpg" height="3438" width="2345" aria-labelledby="f1" loading="lazy"></a><figcaption>Enrollment and Randomization.</figcaption></figure></div><div role="paragraph">A total of 517 patients in the remdesivir group and 508 in the placebo group completed the trial through day 29, recovered, or died. Fourteen patients who received remdesivir and 9 who received placebo terminated their participation in the trial before day 29. A total of 54 of the patients who were in the mild-to-moderate stratum at randomization were subsequently determined to meet the criteria for severe disease, resulting in 105 patients in the mild-to-moderate disease stratum and 957 in the severe stratum. The as-treated population included 1048 patients who received the assigned treatment (532 in the remdesivir group, including one patient who had been randomly assigned to placebo and received remdesivir, and 516 in the placebo group).</div><div role="paragraph">The mean age of the patients was 58.9 years, and 64.4% were male (<a href="#t1">Table 1</a>). On the basis of the evolving epidemiology of Covid-19 during the trial, 79.8% of patients were enrolled at sites in North America, 15.3% in Europe, and 4.9% in Asia (Table S1 in the <a href="#ap1">Supplementary Appendix</a>). Overall, 53.3% of the patients were White, 21.3% were Black, 12.7% were Asian, and 12.7% were designated as other or not reported; 250 (23.5%) were Hispanic or Latino. Most patients had either one (25.9%) or two or more (54.5%) of the prespecified coexisting conditions at enrollment, most commonly hypertension (50.2%), obesity (44.8%), and type 2 diabetes mellitus (30.3%).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2007764_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2007764_t1.jpg"><img src="/cms/10.1056/NEJMoa2007764/asset/62023f30-231c-4440-ba05-bbd2e6f14308/assets/images/large/nejmoa2007764_t1.jpg" height="1882" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">All<br>(N=1062)</th><th class="txxx-borders">Remdesivir<br> (N=541)</th><th class="txxr-borders">Placebo<br>(N=521)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">58.9±15.0</td><td class="xxxx-borders shading">58.6±14.6</td><td class="xxxr-borders shading">59.2±15.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male sex — no. (%)</td><td class="xxxx-borders">684 (64.4)</td><td class="xxxx-borders">352 (65.1)</td><td class="xxxr-borders">332 (63.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race or ethnic group — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">American Indian or Alaska Native</td><td class="xxxx-borders">7 (0.7)</td><td class="xxxx-borders">4 (0.7)</td><td class="xxxr-borders">3 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Asian</td><td class="xxxx-borders shading">135 (12.7)</td><td class="xxxx-borders shading">79 (14.6)</td><td class="xxxr-borders shading">56 (10.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Black or African American</td><td class="xxxx-borders">226 (21.3)</td><td class="xxxx-borders">109 (20.1)</td><td class="xxxr-borders">117 (22.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">White</td><td class="xxxx-borders shading">566 (53.3)</td><td class="xxxx-borders shading">279 (51.6)</td><td class="xxxr-borders shading">287 (55.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Hispanic or Latino — no. (%)</td><td class="xxxx-borders">250 (23.5)</td><td class="xxxx-borders">134 (24.8)</td><td class="xxxr-borders">116 (22.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median time (IQR) from symptom onset to randomization — days<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">9 (6–12)</td><td class="xxxx-borders shading">9 (6–12)</td><td class="xxxr-borders shading">9 (7–13)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">No. of coexisting conditions — no. /total no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">None</td><td class="xxxx-borders shading">194/1048 (18.5)</td><td class="xxxx-borders shading">97/531 (18.3)</td><td class="xxxr-borders shading">97/517 (18.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">One</td><td class="xxxx-borders">275/1048 (26.2)</td><td class="xxxx-borders">138/531 (26.0)</td><td class="xxxr-borders">137/517 (26.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Two or more</td><td class="xxxx-borders shading">579/1048 (55.2)</td><td class="xxxx-borders shading">296/531 (55.7)</td><td class="xxxr-borders shading">283/517 (54.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Coexisting conditions — no./total no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Type 2 diabetes</td><td class="xxxx-borders shading">322/1051 (30.6)</td><td class="xxxx-borders shading">164/532 (30.8)</td><td class="xxxr-borders shading">158/519 (30.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hypertension</td><td class="xxxx-borders shading">533/1051 (50.7)</td><td class="xxxx-borders shading">269/532 (50.6)</td><td class="xxxr-borders shading">264/519 (50.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Obesity</td><td class="xxxx-borders">476/1049 (45.4)</td><td class="xxxx-borders">242/531 (45.6)</td><td class="xxxr-borders">234/518 (45.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Score on ordinal scale — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">4. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (Covid-19–related or otherwise)</td><td class="xxxx-borders shading">138 (13.0)</td><td class="xxxx-borders shading">75 (13.9)</td><td class="xxxr-borders shading">63 (12.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">5. Hospitalized, requiring supplemental oxygen</td><td class="xxxx-borders">435 (41.0)</td><td class="xxxx-borders">232 (42.9)</td><td class="xxxr-borders">203 (39.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">6. Hospitalized, receiving noninvasive ventilation or high-flow oxygen devices</td><td class="xxxx-borders shading">193 (18.2)</td><td class="xxxx-borders shading">95 (17.6)</td><td class="xxxr-borders shading">98 (18.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">7. Hospitalized, receiving invasive mechanical ventilation or ECMO</td><td class="xxxx-borders">285 (26.8)</td><td class="xxxx-borders">131 (24.2)</td><td class="xxxr-borders">154 (29.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Baseline score missing</td><td class="xbxx-borders shading">11 (1.0)</td><td class="xbxx-borders shading">8 (1.5)</td><td class="xbxr-borders shading">3 (0.6)</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. IQR denotes interquartile range, and ECMO extracorporeal membrane oxygenation. The full table of baseline characteristics is available in the <a href="#ap1">Supplementary Appendix</a>.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Race and ethnic group were reported by the patients. The number of patients in other races and ethnic groups are listed in Table S1 in the <a href="#ap1">Supplementary Appendix</a>.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Data on symptom onset were missing for 3 patients; data on coexisting conditions were missing for 11 patients and were incomplete for 3 patients.</div></div></div></figcaption></figure></div><div role="paragraph">The median number of days between symptom onset and randomization was 9 (interquartile range, 6 to 12) (Table S2). A total of 957 patients (90.1%) had severe disease at enrollment; 285 patients (26.8%) met category 7 criteria on the ordinal scale, 193 (18.2%) category 6, 435 (41.0%) category 5, and 138 (13.0%) category 4. Eleven patients (1.0%) had missing ordinal scale data at enrollment; all these patients discontinued the study before treatment. During the study, 373 patients (35.6% of the 1048 patients in the as-treated population) received hydroxychloroquine and 241 (23.0%) received a glucocorticoid (Table S3).</div></section><section id="sec-2-2"><h3>Primary Outcome</h3><div role="paragraph"><a id="exam-tint-one-a"></a><a id="exam-tint-one-b"></a><a id="exam-tint-one-d"></a><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">Patients in the remdesivir group had a shorter time to recovery than patients in the placebo group (median, 10 days, as compared with 15 days; rate ratio for recovery, 1.29; 95% confidence interval [CI], 1.12 to 1.49; P&lt;0.001) (<a href="#f2">Figure 2</a> and <a href="#t2">Table 2</a>).</span> In the severe disease stratum (957 patients) the median time to recovery was 11 days, as compared with 18 days (rate ratio for recovery, 1.31; 95% CI, 1.12 to 1.52) (Table S4). The rate ratio for recovery was largest among patients with a baseline ordinal score of 5 (rate ratio for recovery, 1.45; 95% CI, 1.18 to 1.79); among patients with a baseline score of 4 and those with a baseline score of 6, the rate ratio estimates for recovery were 1.29 (95% CI, 0.91 to 1.83) and 1.09 (95% CI, 0.76 to 1.57), respectively. For those receiving mechanical ventilation or ECMO at enrollment (baseline ordinal score of 7), the rate ratio for recovery was 0.98 (95% CI, 0.70 to 1.36). Information on interactions of treatment with baseline ordinal score as a continuous variable is provided in Table S11. An analysis adjusting for baseline ordinal score as a covariate was conducted to evaluate the overall effect (of the percentage of patients in each ordinal score category at baseline) on the primary outcome. This adjusted analysis produced a similar treatment-effect estimate (rate ratio for recovery, 1.26; 95% CI, 1.09 to 1.46). Patients who underwent randomization during the first 10 days after the onset of symptoms had a rate ratio for recovery of 1.37 (95% CI, 1.14 to 1.64), whereas patients who underwent randomization more than 10 days after the onset of symptoms had a rate ratio for recovery of 1.20 (95% CI, 0.94 to 1.52) (<a href="#f3">Figure 3</a>). <a id="exam-tint-three-d"></a><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="three-d">The benefit of remdesivir was larger when given earlier in the illness, though the benefit persisted in most analyses of duration of symptoms</span> (Table S6). Sensitivity analyses in which data were censored at earliest reported use of glucocorticoids or hydroxychloroquine still showed efficacy of remdesivir (9.0 days to recovery with remdesivir vs. 14.0 days to recovery with placebo; rate ratio, 1.28; 95% CI, 1.09 to 1.50, and 10.0 vs. 16.0 days to recovery; rate ratio, 1.32; 95% CI, 1.11 to 1.58, respectively) (Table S8).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2007764_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2007764_f2.jpg"><img src="/cms/10.1056/NEJMoa2007764/asset/da50d7a4-c678-4ea9-b0f1-c954b76ceed0/assets/images/large/nejmoa2007764_f2.jpg" height="3311" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Kaplan–Meier Estimates of Cumulative Recoveries.</div><div class="notes"><div role="doc-footnote">Cumulative recovery estimates are shown in the overall population (Panel A), in patients with a baseline score of 4 on the ordinal scale (not receiving oxygen; Panel B), in those with a baseline score of 5 (receiving oxygen; Panel C), in those with a baseline score of 6 (receiving high-flow oxygen or noninvasive mechanical ventilation; Panel D), and in those with a baseline score of 7 (receiving mechanical ventilation or extracorporeal membrane oxygenation [ECMO]; Panel E).</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 3</div><nav><a href="#f3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2007764_f3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f3" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2007764_f3.jpg"><img src="/cms/10.1056/NEJMoa2007764/asset/90aee155-1834-41ed-8856-6bc971d387f7/assets/images/large/nejmoa2007764_f3.jpg" height="2019" width="2640" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Time to Recovery According to Subgroup.</div><div class="notes"><div role="doc-footnote">The widths of the confidence intervals have not been adjusted for multiplicity and therefore cannot be used to infer treatment effects. Race and ethnic group were reported by the patients.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2007764_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2007764_t2.jpg"><img src="/cms/10.1056/NEJMoa2007764/asset/5951769f-594e-43de-8bd5-c265d24d19d5/assets/images/large/nejmoa2007764_t2.jpg" height="2311" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><td class="txlx-borders">&nbsp;</td><th class="txxx-borders" colspan="2"><span>Overall</span></th><th class="txxr-borders" colspan="8"><span>Ordinal Score at Baseline</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>4</span></th><th class="xxxx-borders" colspan="2"><span>5</span></th><th class="xxxx-borders" colspan="2"><span>6</span></th><th class="xxxr-borders" colspan="2"><span>7</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Remdesivir<br>(N=541)</th><th class="xxxx-borders">Placebo<br>(N=521)</th><th class="xxxx-borders">Remdesivir<br>(N=75)</th><th class="xxxx-borders">Placebo<br>(N=63)</th><th class="xxxx-borders">Remdesivir<br>(N=232)</th><th class="xxxx-borders">Placebo<br>(N=203)</th><th class="xxxx-borders">Remdesivir<br>(N=95)</th><th class="xxxx-borders">Placebo<br>(N=98)</th><th class="xxxx-borders">Remdesivir<br>(N=131)</th><th class="xxxr-borders">Placebo<br>(N=154)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Recovery</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">No. of recoveries</td><td class="xxxx-borders">399</td><td class="xxxx-borders">352</td><td class="xxxx-borders">73</td><td class="xxxx-borders">58</td><td class="xxxx-borders">206</td><td class="xxxx-borders">156</td><td class="xxxx-borders">57</td><td class="xxxx-borders">61</td><td class="xxxx-borders">63</td><td class="xxxr-borders">77</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Median time to recovery (95% CI) — days</td><td class="xxxx-borders shading">10 (9–11)</td><td class="xxxx-borders shading">15 (13–18)</td><td class="xxxx-borders shading">5 (4–6)</td><td class="xxxx-borders shading">6 (4–7)</td><td class="xxxx-borders shading">7 (6–8)</td><td class="xxxx-borders shading">9 (7–10)</td><td class="xxxx-borders shading">15 (10– 27)</td><td class="xxxx-borders shading">20 (14– 26)</td><td class="xxxx-borders shading">29 (24–NE)</td><td class="xxxr-borders shading">28 (24–NE)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Rate ratio (95% CI)<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders" colspan="2">1.29 (1.12–1.49 [P&lt;0.001])</td><td class="xxxx-borders" colspan="2">1.29 (0.91–1.83)</td><td class="xxxx-borders" colspan="2">1.45 (1.18–1.79)</td><td class="xxxx-borders" colspan="2">1.09 (0.76–1.57)</td><td class="xxxr-borders" colspan="2">0.98 (0.70–1.36)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Mortality through day 14<a href="#t2fn3" role="doc-noteref">‡</a></b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Hazard ratio for data through day 15 (95% CI)</td><td class="xxxx-borders" colspan="2">0.55 (0.36–0.83)</td><td class="xxxx-borders" colspan="2">0.42 (0.04–4.67)</td><td class="xxxx-borders" colspan="2">0.28 (0.12–0.66)</td><td class="xxxx-borders" colspan="2">0.82 (0.40–1.69)</td><td class="xxxr-borders" colspan="2">0.76 (0.39–1.50)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">No. of deaths by day 15</td><td class="xxxx-borders shading">35</td><td class="xxxx-borders shading">61</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">7</td><td class="xxxx-borders shading">21</td><td class="xxxx-borders shading">13</td><td class="xxxx-borders shading">17</td><td class="xxxx-borders shading">14</td><td class="xxxr-borders shading">21</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Kaplan–Meier estimate of mortality by day 15 — % (95% CI)</td><td class="xxxx-borders">6.7<br>(4.8–9.2)</td><td class="xxxx-borders">11.9<br>(9.4–15.0)</td><td class="xxxx-borders">1.3<br>(0.2–9.1)</td><td class="xxxx-borders">3.2<br>(0.8–12.1)</td><td class="xxxx-borders">3.1<br>(1.5–6.4)</td><td class="xxxx-borders">10.5<br>(7.0–15.7)</td><td class="xxxx-borders">14.2<br>(8.5–23.2)</td><td class="xxxx-borders">17.3<br>(11.2–26.4)</td><td class="xxxx-borders">10.9<br>(6.6–17.6)</td><td class="xxxr-borders">13.8<br>(9.2–20.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Mortality over entire study period<a href="#t2fn3" role="doc-noteref">‡</a></b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Hazard ratio (95% CI)</td><td class="xxxx-borders" colspan="2">0.73 (0.52–1.03)</td><td class="xxxx-borders" colspan="2">0.82 (0.17–4.07)</td><td class="xxxx-borders" colspan="2">0.30 (0.14–0.64)</td><td class="xxxx-borders" colspan="2">1.02 (0.54–1.91)</td><td class="xxxr-borders" colspan="2">1.13 (0.67–1.89)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">No. of deaths by day 29</td><td class="xxxx-borders shading">59</td><td class="xxxx-borders shading">77</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">9</td><td class="xxxx-borders shading">25</td><td class="xxxx-borders shading">19</td><td class="xxxx-borders shading">20</td><td class="xxxx-borders shading">28</td><td class="xxxr-borders shading">29</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Kaplan–Meier estimate of mortality by day 29 — % (95% CI)</td><td class="xxxx-borders">11.4<br>(9.0–14.5)</td><td class="xxxx-borders">15.2<br>(12.3–18.6)</td><td class="xxxx-borders">4.1<br>(1.3– 12.1)</td><td class="xxxx-borders">4.8<br>(1.6–14.3)</td><td class="xxxx-borders">4.0<br>(2.1–7.5)</td><td class="xxxx-borders">12.7<br>(8.8–18.3)</td><td class="xxxx-borders">21.2<br>(14.0–31.2)</td><td class="xxxx-borders">20.4<br>(13.7–29.8)</td><td class="xxxx-borders">21.9<br>(15.7–30.1)</td><td class="xxxr-borders">19.3<br>(13.8–26.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Ordinal score at day 15 (±2 days) — no. (%)<a href="#t2fn4" role="doc-noteref">§</a></b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">1</td><td class="xxxx-borders">157 (29.0)</td><td class="xxxx-borders">115 (22.1)</td><td class="xxxx-borders">38 (50.7)</td><td class="xxxx-borders">28 (44.4)</td><td class="xxxx-borders">90 (38.8)</td><td class="xxxx-borders">62 (30.5)</td><td class="xxxx-borders">18 (18.9)</td><td class="xxxx-borders">14 (14.3)</td><td class="xxxx-borders">11 (8.4)</td><td class="xxxr-borders">11 (7.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">2</td><td class="xxxx-borders shading">117 (21.6)</td><td class="xxxx-borders shading">102 (19.6)</td><td class="xxxx-borders shading">20 (26.7)</td><td class="xxxx-borders shading">15 (23.8)</td><td class="xxxx-borders shading">70 (30.2)</td><td class="xxxx-borders shading">58 (28.6)</td><td class="xxxx-borders shading">22 (23.2)</td><td class="xxxx-borders shading">19 (19.4)</td><td class="xxxx-borders shading">5 (3.8)</td><td class="xxxr-borders shading">10 (6.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">3</td><td class="xxxx-borders">14 (2.6)</td><td class="xxxx-borders">8 (1.5)</td><td class="xxxx-borders">8 (10.7)</td><td class="xxxx-borders">4 (6.3)</td><td class="xxxx-borders">6 (2.6)</td><td class="xxxx-borders">4 (2.0)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">4</td><td class="xxxx-borders shading">38 (7.0)</td><td class="xxxx-borders shading">33 (6.3)</td><td class="xxxx-borders shading">3 (4.0)</td><td class="xxxx-borders shading">7 (11.1)</td><td class="xxxx-borders shading">17 (7.3)</td><td class="xxxx-borders shading">13 (6.4)</td><td class="xxxx-borders shading">12 (12.6)</td><td class="xxxx-borders shading">4 (4.1)</td><td class="xxxx-borders shading">6 (4.6)</td><td class="xxxr-borders shading">9 (5.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">5</td><td class="xxxx-borders">58 (10.7)</td><td class="xxxx-borders">60 (11.5)</td><td class="xxxx-borders">3 (4.0)</td><td class="xxxx-borders">5 (7.9)</td><td class="xxxx-borders">25 (10.8)</td><td class="xxxx-borders">18 (8.9)</td><td class="xxxx-borders">2 (2.1)</td><td class="xxxx-borders">14 (14.3)</td><td class="xxxx-borders">28 (21.4)</td><td class="xxxr-borders">23 (14.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">6</td><td class="xxxx-borders shading">28 (5.2)</td><td class="xxxx-borders shading">24 (4.6)</td><td class="xxxx-borders shading">1 (1.3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">5 (2.2)</td><td class="xxxx-borders shading">7 (3.4)</td><td class="xxxx-borders shading">12 (12.6)</td><td class="xxxx-borders shading">11 (11.2)</td><td class="xxxx-borders shading">10 (7.6)</td><td class="xxxr-borders shading">6 (3.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">7</td><td class="xxxx-borders">95 (17.6)</td><td class="xxxx-borders">121 (23.2)</td><td class="xxxx-borders">1 (1.3)</td><td class="xxxx-borders">3 (4.8)</td><td class="xxxx-borders">13 (5.6)</td><td class="xxxx-borders">21 (10.3)</td><td class="xxxx-borders">16 (16.8)</td><td class="xxxx-borders">20 (20.4)</td><td class="xxxx-borders">57 (43.5)</td><td class="xxxr-borders">74 (48.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">8</td><td class="xxxx-borders shading">34 (6.3)</td><td class="xxxx-borders shading">58 (11.1)</td><td class="xxxx-borders shading">1 (1.3)</td><td class="xxxx-borders shading">1 (1.6)</td><td class="xxxx-borders shading">6 (2.6)</td><td class="xxxx-borders shading">20 (9.9)</td><td class="xxxx-borders shading">13 (13.7)</td><td class="xxxx-borders shading">16 (16.3)</td><td class="xxxx-borders shading">14 (10.7)</td><td class="xxxr-borders shading">21 (13.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Odds ratio (95% CI)</td><td class="xbxx-borders" colspan="2">1.5 (1.2–1.9)</td><td class="xbxx-borders" colspan="2">1.5 (0.8–2.7)</td><td class="xbxx-borders" colspan="2">1.6 (1.2–2.3)</td><td class="xbxx-borders" colspan="2">1.4 (0.9–2.3)</td><td class="xbxr-borders" colspan="2">1.2 (0.8–1.9)</td></tr></tbody></table></div><figcaption><div class="caption">Outcomes Overall and According to Score on the Ordinal Scale in the Intention-to-Treat Population.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">P values and confidence intervals have not been adjusted for multiple comparisons. NE denotes not possible to estimate.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">Recovery rate ratios and hazard ratios were calculated from the stratified Cox model; the P value for this ratio was calculated with the stratified log-rank test (overall model stratified by actual disease severity). Recovery rate ratios greater than 1 indicate a benefit with remdesivir; hazard ratios less than 1 indicate a benefit with remdesivir.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">Mortality over the first 14 days includes data from all patients who were still alive through 14 days postenrollment, with data censored on day 15, as if 14 days was the maximum follow-up time. Mortality over the entire study period uses the totality of the study data and censors data from patients who completed follow-up alive at 28 days postenrollment.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">The ordinal score at day 15 is the patient’s worst score on the ordinal scale during the previous day. Four patients died 15 days after randomization and are recorded as having died for the ordinal score at the day 15 outcome but not for the mortality day 15 outcome. Scores on the ordinal scale are as follows: 1, not hospitalized, no limitations of activities; 2, not hospitalized, limitation of activities, home oxygen requirement, or both; 3, hospitalized, not requiring supplemental oxygen and no longer requiring ongoing medical care (used if hospitalization was extended for infection-control reasons); 4, hospitalized, not requiring supplemental oxygen but requiring ongoing medical care (Covid-19–related or other medical conditions); 5, hospitalized, requiring any supplemental oxygen; 6, hospitalized, requiring noninvasive ventilation or use of high-flow oxygen devices; 7, hospitalized, receiving invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); and 8, death. Odds ratios and P values were calculated with the use of a proportional odds model (overall model adjusted for actual disease severity). Odds ratio values greater than 1 indicate a benefit with remdesivir.</div></div></div></figcaption></figure></div></section><section id="sec-2-3"><h3>Key Secondary Outcome</h3><div role="paragraph">The odds of improvement in the ordinal scale score were higher in the remdesivir group, as determined by a proportional odds model at the day 15 visit, than in the placebo group (odds ratio for improvement, 1.5; 95% CI, 1.2 to 1.9, adjusted for disease severity) (<a href="#t2">Table 2</a> and Fig. S7).</div></section><section id="sec-2-4"><h3>Mortality</h3><div role="paragraph"><a id="exam-tint-three-b"></a><span id="tint5" class="named-content" data-type="exam-tint" data-answer-ids="three-b">Kaplan–Meier estimates of mortality by day 15 were 6.7% in the remdesivir group and 11.9% in the placebo group (hazard ratio, 0.55; 95% CI, 0.36 to 0.83); the estimates by day 29 were 11.4% and 15.2% in two groups, respectively (hazard ratio, 0.73; 95% CI, 0.52 to 1.03).</span> The between-group differences in mortality varied considerably according to baseline severity (<a href="#t2">Table 2</a>), with the largest difference seen among patients with a baseline ordinal score of 5 (hazard ratio, 0.30; 95% CI, 0.14 to 0.64). Information on interactions of treatment with baseline ordinal score with respect to mortality is provided in Table S11.</div></section><section id="sec-2-5"><h3>Additional Secondary Outcomes</h3><div role="paragraph">Patients in the remdesivir group had a shorter time to improvement of one or of two categories on the ordinal scale from baseline than patients in the placebo group (one-category improvement: median, 7 vs. 9 days; rate ratio for recovery, 1.23; 95% CI, 1.08 to 1.41; two-category improvement: median, 11 vs. 14 days; rate ratio, 1.29; 95% CI, 1.12 to 1.48) (<a href="#t3">Table 3</a>). Patients in the remdesivir group had a shorter time to discharge or to a National Early Warning Score of 2 or lower than those in the placebo group (median, 8 days vs. 12 days; hazard ratio, 1.27; 95% CI, 1.10 to 1.46). <a id="exam-tint-three-a"></a><span id="tint6" class="named-content" data-type="exam-tint" data-answer-ids="three-a">The initial length of hospital stay was shorter in the remdesivir group than in the placebo group (median, 12 days vs. 17 days); 5% of patients in the remdesivir group were readmitted to the hospital, as compared with 3% in the placebo group.</span></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2007764_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2007764_t3.jpg"><img src="/cms/10.1056/NEJMoa2007764/asset/f7563782-e109-4d5f-ab97-73e5d2b31c70/assets/images/large/nejmoa2007764_t3.jpg" height="2150" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><td class="txlx-borders">&nbsp;</td><th class="txxx-borders">Remdesivir<br>(N=541)</th><th class="txxx-borders">Placebo<br>(N=521)</th><th class="txxr-borders">Rate Ratio<br>(95% CI)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Median time to clinical improvement (95% CI) — days</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Improvement of one category on ordinal scale</td><td class="xxxx-borders">7.0 (6.0 to 8.0)</td><td class="xxxx-borders">9.0 (8.0 to 11.0)</td><td class="xxxr-borders">1.23 (1.08 to 1.41)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Improvement of two categories on ordinal scale</td><td class="xxxx-borders shading">11.0 (10.0 to 13.0)</td><td class="xxxx-borders shading">14.0 (13.0 to 15.0)</td><td class="xxxr-borders shading">1.29 (1.12 to 1.48)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Discharge or National Early Warning Score ≤2 for 24 hr<a href="#t3fn1" role="doc-noteref">*</a></td><td class="xxxx-borders">8.0 (7.0 to 9.0)</td><td class="xxxx-borders">12.0 (10.0 to 15.0)</td><td class="xxxr-borders">1.27 (1.10 to 1.46)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading"><b>Difference (95% CI)</b></td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Hospitalization</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median duration of initial hospitalization (IQR) — days<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">12 (6 to 28)</td><td class="xxxx-borders shading">17 (8 to 28)</td><td class="xxxr-borders shading">−5.0 (−7.7 to −2.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median duration of initial hospitalization among those who did not die (IQR) — days</td><td class="xxxx-borders">10 (5 to 21)</td><td class="xxxx-borders">14 (7 to 27)</td><td class="xxxr-borders">−4.0 (−6.0 to −2.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Patients rehospitalized — % (95% CI)</td><td class="xxxx-borders shading">5 (3 to 7)</td><td class="xxxx-borders shading">3 (2 to 5)</td><td class="xxxr-borders shading">2 percentage points<br>(0 to 4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Oxygen</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median days receiving oxygen if receiving oxygen at baseline (IQR)</td><td class="xxxx-borders shading">13 (5 to 28)</td><td class="xxxx-borders shading">21 (8 to 28)</td><td class="xxxr-borders shading">−8.0 (−11.8 to −4.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">New use of oxygen</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of patients/total no.</td><td class="xxxx-borders shading">27/75</td><td class="xxxx-borders shading">28/63</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Percent of patients (95% CI)</td><td class="xxxx-borders">36 (26 to 47)</td><td class="xxxx-borders">44 (33 to 57)</td><td class="xxxr-borders">−8 (−24 to 8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Median days receiving oxygen (IQR)</td><td class="xxxx-borders shading">4 (2 to 12)</td><td class="xxxx-borders shading">5.5 (1 to 15)</td><td class="xxxr-borders shading">−1.0 (−7.6 to 5.6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Noninvasive ventilation or high-flow oxygen</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median days of noninvasive ventilation or high-flow oxygen use during study if receiving these interventions at baseline (IQR)</td><td class="xxxx-borders shading">6 (3 to 18)</td><td class="xxxx-borders shading">6 (3 to 16)</td><td class="xxxr-borders shading">0 (−2.6 to 2.6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">New use of new noninvasive ventilation or high-flow oxygen use during the study</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of patients/total no.</td><td class="xxxx-borders shading">52/307</td><td class="xxxx-borders shading">64/266</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Percent of patients (95% CI)</td><td class="xxxx-borders">17 (13 to 22)</td><td class="xxxx-borders">24 (19 to 30)</td><td class="xxxr-borders">−7 (−14 to −1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Median days of use during the study (IQR)</td><td class="xxxx-borders shading">3 (1 to 10.5)</td><td class="xxxx-borders shading">4 (2 to 23.5)</td><td class="xxxr-borders shading">−1.0 (−4.0 to 2.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Mechanical ventilation or ECMO</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median days of mechanical ventilation or ECMO during study if receiving these interventions at baseline (IQR)</td><td class="xxxx-borders shading">17 (9 to 28)</td><td class="xxxx-borders shading">20 (8 to 28)</td><td class="xxxr-borders shading">−3.0 (−9.3 to 3.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">New use of mechanical ventilation or ECMO during study</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of patients/total no.</td><td class="xxxx-borders shading">52/402</td><td class="xxxx-borders shading">82/364</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Percent of patients (95% CI)</td><td class="xxxx-borders">13 (10 to 17)</td><td class="xxxx-borders">23 (19 to 27)</td><td class="xxxr-borders">−10 (−15 to −4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Median days of use during the study (IQR)</td><td class="xbxx-borders shading">21.5 (9 to 28)</td><td class="xbxx-borders shading">23 (12 to 28)</td><td class="xbxr-borders shading">1.0 (−6.0 to 8.0)</td></tr></tbody></table></div><figcaption><div class="caption">Additional Secondary Outcomes.</div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">The National Early Warning Score includes six physiological measures; total scores range from 0 to 20, with higher scores indicating greater clinical risk.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">The duration of initial hospitalization for patients who died was imputed as 28 days.</div></div></div></figcaption></figure></div><div role="paragraph">Among the 913 patients receiving oxygen at enrollment, those in the remdesivir group continued to receive oxygen for fewer days than patients in the placebo group (median, 13 days vs. 21 days), and the incidence of new oxygen use among patients who were not receiving oxygen at enrollment was lower in the remdesivir group than in the placebo group (incidence, 36% [95% CI, 26 to 47] vs. 44% [95% CI, 33 to 57]). For the 193 patients receiving noninvasive ventilation or high-flow oxygen at enrollment, the median duration of use of these interventions was 6 days in both the remdesivir and placebo groups. Among the 573 patients who were not receiving noninvasive ventilation, high-flow oxygen, invasive ventilation, or ECMO at baseline, the incidence of new noninvasive ventilation or high-flow oxygen use was lower in the remdesivir group than in the placebo group (17% [95% CI, 13 to 22] vs. 24% [95% CI, 19 to 30]). Among the 285 patients who were receiving mechanical ventilation or ECMO at enrollment, patients in the remdesivir group received these interventions for fewer subsequent days than those in the placebo group (median, 17 days vs. 20 days), and the incidence of new mechanical ventilation or ECMO use among the 766 patients who were not receiving these interventions at enrollment was lower in the remdesivir group than in the placebo group (13% [95% CI, 10 to 17] vs. 23% [95% CI, 19 to 27]) (<a href="#t3">Table 3</a>).</div></section><section id="sec-2-6"><h3>Safety Outcomes</h3><div role="paragraph">In the as-treated population, serious adverse events occurred in 131 of 532 patients (24.6%) in the remdesivir group and in 163 of 516 patients (31.6%) in the placebo group (Table S17). There were 47 serious respiratory failure adverse events in the remdesivir group (8.8% of patients), including acute respiratory failure and the need for endotracheal intubation, and 80 in the placebo group (15.5% of patients) (Table S19). No deaths were considered by the investigators to be related to treatment assignment.</div><div role="paragraph">Grade 3 or 4 adverse events occurred on or before day 29 in 273 patients (51.3%) in the remdesivir group and in 295 (57.2%) in the placebo group (Table S18); 41 events were judged by the investigators to be related to remdesivir and 47 events to placebo (Table S17). The most common nonserious adverse events occurring in at least 5% of all patients included decreased glomerular filtration rate, decreased hemoglobin level, decreased lymphocyte count, respiratory failure, anemia, pyrexia, hyperglycemia, increased blood creatinine level, and increased blood glucose level (Table S20). The incidence of these adverse events was generally similar in the remdesivir and placebo groups.</div></section><section id="sec-2-7"><h3>Crossover</h3><div role="paragraph">After the data and safety monitoring board recommended that the preliminary primary analysis report be provided to the sponsor, data on a total of 51 patients (4.8% of the total study enrollment) — 16 (3.0%) in the remdesivir group and 35 (6.7%) in the placebo group — were unblinded; 26 (74.3%) of those in the placebo group whose data were unblinded were given remdesivir. Sensitivity analyses evaluating the unblinding (patients whose treatment assignments were unblinded had their data censored at the time of unblinding) and crossover (patients in the placebo group treated with remdesivir had their data censored at the initiation of remdesivir treatment) produced results similar to those of the primary analysis (Table S9).</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">This double-blind, randomized, placebo-controlled trial identified an antiviral therapy as beneficial in the treatment of Covid-19. Our overall findings were consistent with the findings of the preliminary report: a 10-day course of remdesivir was superior to placebo in the treatment of hospitalized patients with Covid-19. Patients who received remdesivir had a shorter time to recovery (the primary end point) than those who received placebo (median, 10 days vs. 15 days; rate ratio for recovery, 1.29 [95% CI, 1.12 to 1.49]) and were more likely to have improvement in the ordinal scale score at day 15 (key secondary end point; odds ratio, 1.5; 95% CI, 1.2 to 1.9). Additional secondary end points supporting these findings include remdesivir treatment resulting in a shorter time to improvement of one and of two ordinal scale categories, a shorter time to discharge or to a sustained National Early Warning Score of 2 or lower, and a shorter length of initial hospital stay (median, 12 days vs. 17 days). All-cause mortality was 11.4% with remdesivir and 15.2% with placebo (hazard ratio, 0.73; 95% CI, 0.52 to 1.03).</div><div role="paragraph">Our data also suggest that treatment with remdesivir may have prevented the progression to more severe respiratory disease, as shown by the lower proportion of serious adverse events due to respiratory failure among patients in the remdesivir group, as well as a lower incidence of new oxygen use among patients who were not receiving oxygen at enrollment and a lower proportion of patients needing higher levels of respiratory support during the study. Treatment with remdesivir was associated with fewer days of subsequent oxygen use for patients receiving oxygen at enrollment and shorter subsequent duration of mechanical ventilation or ECMO for those receiving these interventions at enrollment. Cumulatively, these findings suggest that treatment with remdesivir may not only reduce the disease burden but may also decrease the use of scarce health care resources during this pandemic. The benefit in recovery persisted when adjustment was made for glucocorticoid use, which suggests that the benefit of dexamethasone as shown in the Randomized Evaluation of Covid-19 Therapy (RECOVERY) trial<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4-2" href-manipulated="true" aria-label="Reference 4">4</a></sup> may be additive to that of remdesivir.</div><div role="paragraph"><a id="exam-tint-two-a"></a><a id="exam-tint-two-b"></a><a id="exam-tint-two-c"></a><a id="exam-tint-two-d"></a><span id="tint7" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b two-c two-d">The benefit of remdesivir was most apparent in patients with a baseline ordinal score of 5 (receiving low-flow oxygen). Some of this difference may be due to the larger sample size in this category since confidence intervals for baseline ordinal scores of 4 (not receiving oxygen), 6 (receiving high-flow oxygen), and 7 (receiving ECMO or mechanical ventilation) were wide. However, the interaction tests suggest greater benefit (with respect to recovery and mortality) in lower ordinal score categories. This should not be interpreted as conclusively showing a lack of efficacy in higher ordinal score categories. The median recovery time for patients in category 7 could not be estimated, which suggests that the follow-up time may have been too short to evaluate that subgroup.</span></div><div role="paragraph">The findings in our trial should be compared with those observed in other randomized trials of remdesivir. Wang et al. enrolled 237 patients (158 assigned to remdesivir and 79 to placebo) in China early in the pandemic and showed a shorter time to improvement (a two-point improvement) with remdesivir: 21.0 days (95% CI, 13.0 to 28.0) in the remdesivir group and 23.0 days (95% CI, 15.0 to 28.0) in the placebo group (hazard ratio for clinical improvement, 1.23; 95% CI, 0.87 to 1.75).<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14" href-manipulated="true" aria-label="Reference 14">14</a></sup> That trial did not complete full enrollment owing to local control of the outbreak, had lower power than ACTT-1 owing to the smaller sample size and a 2:1 randomization, and was unable to demonstrate any statistically significant clinical benefits of remdesivir. In the recently published, open-label, randomized study of remdesivir in hospitalized patients with moderate-severity Covid-19 (83% were not receiving oxygen at baseline), patients who received remdesivir for 5 days had higher odds of clinical improvement than those receiving standard care (odds ratio, 1.65; 95% CI, 1.09 to 2.48; P=0.02). This benefit was not seen with the 10-day course (P=0.18).<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15" href-manipulated="true" aria-label="Reference 15">15</a></sup> We believe that these other studies support our findings regarding the efficacy of remdesivir; however, our study was larger, blinded, and fully enrolled.</div><div role="paragraph">The primary outcome of the current trial was changed early in the trial, from a comparison of the eight-category ordinal scale scores on day 15 to a comparison of time to recovery up to day 29. Little was known about the natural clinical course of Covid-19 when the trial was designed in February 2020. Emerging data suggested that Covid-19 had a more protracted course than was previously known, which aroused concern that a difference in outcome after day 15 would have been missed by a single assessment at day 15. The amendment was proposed on March 22, 2020, by trial statisticians who were unaware of treatment assignment and had no knowledge of outcome data; when this change was proposed 72 patients had been enrolled. Although changes in the primary outcome are not common in trials for diseases that are well understood, it is recognized that in some trials, such as those involving poorly understood diseases, circumstances may require a change in the way an outcome is assessed or may necessitate a different outcome.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16" href-manipulated="true" aria-label="Reference 16">16</a></sup> The original primary outcome became the key secondary end point. In the end, findings for both primary and key secondary end points were significantly different between the remdesivir and placebo groups.</div><div role="paragraph">Numerous challenges were encountered during this trial. The trial was implemented during a time of restricted travel, and hospitals restricted the entrance of nonessential personnel. Training, site initiation visits, and monitoring visits often were performed remotely. Research staff were often assigned other clinical duties, and staff illnesses strained research resources. Many sites did not have adequate supplies of personal protective equipment and trial-related supplies, such as swabs. However, research teams were motivated to find creative solutions to overcome these challenges. Throughout the trial, we were able to enroll a diverse population, similar to the population that was being infected with SARS-CoV-2 during that period.</div><div role="paragraph">Given the preliminary results about remdesivir, the Food and Drug Administration issued an Emergency Use Authorization on May 1, 2020 (modified on August 28, 2020), to permit the use of remdesivir for treatment in adults and children hospitalized with suspected or laboratory-confirmed Covid-19. Remdesivir has also received full or conditional approval in several other countries since that time. However, given high mortality despite the use of remdesivir, it is clear that treatment with an antiviral drug alone is not likely to be sufficient for all patients. Current strategies are evaluating remdesivir in combination with modifiers of the immune response (e.g., the Janus kinase [JAK] inhibitor baricitinib in ACTT-2, and interferon beta-1a in ACTT-3). A variety of therapeutic approaches including novel antivirals, modifiers of the immune response or other intrinsic pathways, and combination approaches are needed to continue to improve outcomes in patients with Covid-19.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="disclaimer" role="paragraph">The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, the Uniformed Services University of the Health Sciences, the Henry M. Jackson Foundation for the Advancement of Military Medicine, the Departments of the Army, Navy, or Air Force, the Department of Defense, or the Department of Veterans Affairs, nor does any mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. Gilead Sciences provided remdesivir for use in this trial but did not provide any financial support. Employees of Gilead Sciences participated in discussions about protocol development and in weekly protocol team calls. The National Institute of Allergy and Infectious Diseases (NIAID) ultimately made all decisions regarding trial design and implementation.</div><div data-type="published/updated" role="paragraph">A <a href="#ap5">preliminary version</a> of this article was published on May 22, 2020, at NEJM.org. This article was published on October 8, 2020, and updated on October 9, 2020, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap3">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">The trial was sponsored and primarily funded by the <span class="named-content" data-type="funder">NIAID</span>, National Institutes of Health (NIH), Bethesda, MD. This trial has been funded in part with federal funds from the <span class="named-content" data-type="funder">NIAID</span> and the <span class="named-content" data-type="funder">National Cancer Institute</span>, NIH, under contract HHSN261200800001E 75N910D00024, task order number 75N91019F00130/75N91020F00010, and by the Department of Defense, Defense Health Program. This trial has been supported in part by the <span class="named-content" data-type="funder">NIAID of the NIH</span>under award numbers UM1AI148684, UM1AI148576, UM1AI148573, UM1AI148575, UM1AI148452, UM1AI148685, UM1AI148450, and UM1AI148689. The trial has also been funded in part by the governments of Denmark, Japan, Mexico, and Singapore. The trial site in South Korea received funding from the Seoul National University Hospital. Support for the London International Coordinating Centre was also provided by the United Kingdom Medical Research Council (MRC_UU_12023/23).</div><div role="paragraph">Dr. Chu reports receiving consulting fees from Merck and GlaxoSmithKline, grant support from Sanofi Pasteur, and research supplies from Cepheid, Ellume, and Genentech; Dr. Luetkemeyer, receiving grant support, paid to the University of California, San Francisco, from Gilead; Dr. Paredes, receiving grant support and advisory fees from Gilead Sciences, Merck Sharp and Dohme, and ViiV Healthcare; Dr. Touloumi, receiving grant support from Gilead Sciences Europe; Dr. Benfield, receiving grant support from Pfizer, Novo Nordisk Foundation, Simonsen Foundation, and Lundbeck Foundation, grant support and advisory board fees from GlaxoSmithKline, grant support and lecture fees from Pfizer, teaching fees from Boehringer Ingelheim, grant support and teaching fees from Gilead, and teaching fees and advisory board fees from Merck Sharp and Dohme; Dr. Fätkenheuer, receiving grant support, advisory board fees, and travel support from Gilead Sciences and Janssen and grant support and advisory board fees from Merck Sharp and Dohme and ViiV Healthcare; Dr. Kortepeter, receiving consulting fees and serving on a board for Integrum Scientific; Dr. Pett, receiving grant support from Gilead Sciences and ViiV Healthcare; and Dr. Osinusi, being employed by Gilead Sciences. No other potential conflict of interest relevant to this article was reported.</div><div role="paragraph"><a href="#ap2">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the members of the ACTT-1 Study Group (see the <a href="#ap1">Supplementary Appendix</a>) for their many contributions in conducting the trial, the members of the data and safety monitoring board (Michael G. Ison, M.D. [chair], Northwestern University Feinberg School of Medicine; Nina Singh, M.D., University of Pittsburgh; Bernd Salzberger, M.D., Ph.D., University of Regensburg; Wendy Leisenring, Sc.D., Fred Hutchinson Cancer Research Center; and Peter Sasieni, Ph.D., King’s College London) for their oversight, and the patients themselves for their altruism in participating in this trial.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2007764_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2007764/suppl_file/nejmoa2007764_appendix.pdf" download="nejmoa2007764_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2007764_appendix.pdf" data-doi="10.1056/NEJMoa2007764">Download</a></li><li>2.53 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2007764_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2007764/suppl_file/nejmoa2007764_disclosures.pdf" download="nejmoa2007764_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2007764_disclosures.pdf" data-doi="10.1056/NEJMoa2007764">Download</a></li><li>810.85 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2007764_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2007764/suppl_file/nejmoa2007764_data-sharing.pdf" download="nejmoa2007764_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2007764_data-sharing.pdf" data-doi="10.1056/NEJMoa2007764">Download</a></li><li>67.68 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2007764_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2007764/suppl_file/nejmoa2007764_protocol.pdf" download="nejmoa2007764_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2007764_protocol.pdf" data-doi="10.1056/NEJMoa2007764">Download</a></li><li>5.29 MB</li></ul></div></div><div id="ap5" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Preliminary Version of this Article</span> <span class="core-filename">(nejmoa2007764_preliminary-report.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2007764/suppl_file/nejmoa2007764_preliminary-report.pdf" download="nejmoa2007764_preliminary-report.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2007764_preliminary-report.pdf" data-doi="10.1056/NEJMoa2007764">Download</a></li><li>624.18 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. <em>J Clin Med</em> 2020;9(4):E1225-E1225.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3390/jcm9041225" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32344679/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000531821000332" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+COVID-19+pandemic%3A+a+comprehensive+review+of+taxonomy%2C+genetics%2C+epidemiology%2C+diagnosis%2C+treatment%2C+and+control.&amp;publication_year=2020&amp;journal=J+Clin+Med&amp;pages=E1225-E1225&amp;doi=10.3390%2Fjcm9041225&amp;pmid=32344679" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. <em>N Engl J Med</em> 2020;382:1787-1799.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_3_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2007764&amp;key=10.1056%2FNEJMoa2001282&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32187464/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000533411000010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+trial+of+lopinavir%E2%80%93ritonavir+in+adults+hospitalized+with+severe+Covid-19.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=1787-1799&amp;doi=10.1056%2FNEJMoa2001282&amp;pmid=32187464" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. <em>JAMA Netw Open</em> 2020;3(4):e208857-e208857.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamanetworkopen.2020.8857" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32330277/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000529959400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+high+vs+low+doses+of+chloroquine+diphosphate+as+adjunctive+therapy+for+patients+hospitalized+with+severe+acute+respiratory+syndrome+coronavirus+2+%28SARS-CoV-2%29+infection%3A+a+randomized+clinical+trial.&amp;publication_year=2020&amp;journal=JAMA+Netw+Open&amp;pages=e208857-e208857&amp;doi=10.1001%2Fjamanetworkopen.2020.8857&amp;pmid=32330277" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. <em>N Engl J Med</em>.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_5_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2007764&amp;key=10.1056%2FNEJMoa2021436&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000623807600009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dexamethasone+in+hospitalized+patients+with+Covid-19+%E2%80%94+preliminary+report&amp;doi=10.1056%2FNEJMoa2021436" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] receiving invasive mechanical ventilation. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of Covid-19 Therapy (RECOVERY) trial </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. <em>Nat Commun</em> 2020;11:222-222.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41467-019-13940-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31924756/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000551460900006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+therapeutic+efficacy+of+remdesivir+and+combination+lopinavir%2C+ritonavir%2C+and+interferon+beta+against+MERS-CoV.&amp;publication_year=2020&amp;journal=Nat+Commun&amp;pages=222-222&amp;doi=10.1038%2Fs41467-019-13940-6&amp;pmid=31924756" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. <em>mBio</em> 2018;9(2):e00221-18-e00221-18.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/mBio.00221-18" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29511076/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000431279600020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Coronavirus+susceptibility+to+the+antiviral+remdesivir+%28GS-5734%29+is+mediated+by+the+viral+polymerase+and+the+proofreading+exoribonuclease.&amp;publication_year=2018&amp;journal=mBio&amp;pages=e00221-18-e00221-18&amp;doi=10.1128%2FmBio.00221-18&amp;pmid=29511076" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. <em>Antiviral Res</em> 2019;169:104541-104541.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.antiviral.2019.104541" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31233808/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000499934800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Broad+spectrum+antiviral+remdesivir+inhibits+human+endemic+and+zoonotic+deltacoronaviruses+with+a+highly+divergent+RNA+dependent+RNA+polymerase.&amp;publication_year=2019&amp;journal=Antiviral+Res&amp;pages=104541-104541&amp;doi=10.1016%2Fj.antiviral.2019.104541&amp;pmid=31233808" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. <em>Sci Transl Med</em> 2017;9:eaal3653-eaal3653.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/scitranslmed.aal3653" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28659436/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000404239400002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Broad-spectrum+antiviral+GS-5734+inhibits+both+epidemic+and+zoonotic+coronaviruses.&amp;publication_year=2017&amp;journal=Sci+Transl+Med&amp;pages=eaal3653-eaal3653&amp;doi=10.1126%2Fscitranslmed.aal3653&amp;pmid=28659436" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. <em>Cell Res</em> 2020;30:269-271.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41422-020-0282-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32020029/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000511096100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Remdesivir+and+chloroquine+effectively+inhibit+the+recently+emerged+novel+coronavirus+%282019-nCoV%29+in+vitro.&amp;publication_year=2020&amp;journal=Cell+Res&amp;pages=269-271&amp;doi=10.1038%2Fs41422-020-0282-0&amp;pmid=32020029" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">de Wit E, Rasmussen AL, Falzarano D, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. <em>Proc Natl Acad Sci U S A</em> 2013;110:16598-16603.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1073/pnas.1310744110" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24062443/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325395600071" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Middle+East+respiratory+syndrome+coronavirus+%28MERS-CoV%29+causes+transient+lower+respiratory+tract+infection+in+rhesus+macaques.&amp;publication_year=2013&amp;journal=Proc+Natl+Acad+Sci+U+S+A&amp;pages=16598-16603&amp;doi=10.1073%2Fpnas.1310744110&amp;pmid=24062443" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. <em>Proc Natl Acad Sci U S A</em> 2020;117:6771-6776.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1073/pnas.1922083117" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32054787/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000521821800064" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Prophylactic+and+therapeutic+remdesivir+%28GS-5734%29+treatment+in+the+rhesus+macaque+model+of+MERS-CoV+infection.&amp;publication_year=2020&amp;journal=Proc+Natl+Acad+Sci+U+S+A&amp;pages=6771-6776&amp;doi=10.1073%2Fpnas.1922083117&amp;pmid=32054787" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Royal College of Physicians. National Early Warning Score (NEWS) 2. 2017 (<a href="https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2">https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Royal+College+of+Physicians.+National+Early+Warning+Score+%28NEWS%29+2.+2017+%28https%3A%2F%2Fwww.rcplondon.ac.uk%2Fprojects%2Foutputs%2Fnational-early-warning-score-news-2%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">King JC, Beigel JH, Ison MG, et al. Clinical development of therapeutic agents for hospitalized patients with influenza: challenges and innovations. <em>Open Forum Infect Dis</em> 2019;6:ofz137-ofz137.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/ofid/ofz137" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31037242/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000474844200041" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+development+of+therapeutic+agents+for+hospitalized+patients+with+influenza%3A+challenges+and+innovations.&amp;publication_year=2019&amp;journal=Open+Forum+Infect+Dis&amp;pages=ofz137-ofz137&amp;doi=10.1093%2Fofid%2Fofz137&amp;pmid=31037242" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. <em>Lancet</em> 2020;395:1569-1578.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)31022-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32423584/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000536542900023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Remdesivir+in+adults+with+severe+COVID-19%3A+a+randomised%2C+double-blind%2C+placebo-controlled%2C+multicentre+trial.&amp;publication_year=2020&amp;journal=Lancet&amp;pages=1569-1578&amp;doi=10.1016%2FS0140-6736%2820%2931022-9&amp;pmid=32423584" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. <em>JAMA</em> 2020;324:1048-1057.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2020.16349" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32821939/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000581077300019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+remdesivir+vs+standard+care+on+clinical+status+at+11+days+in+patients+with+moderate+COVID-19%3A+a+randomized+clinical+trial.&amp;publication_year=2020&amp;journal=JAMA&amp;pages=1048-1057&amp;doi=10.1001%2Fjama.2020.16349&amp;pmid=32821939" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">The CONSORT Group. 3b. Changes to trial design (<a href="http://www.consort-statement.org/consort-2010">http://www.consort-statement.org/consort-2010</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=The+CONSORT+Group.+3b.+Changes+to+trial+design+%28http%3A%2F%2Fwww.consort-statement.org%2Fconsort-2010%29." target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/383/19"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">383</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">19</span></span> • <span property="datePublished">November 5, 2020</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1813</span>-<span property="pageEnd">1826</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2020 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa2007764" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa2007764?sg=AbW1N">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: May 22, 2020</div><div><b class="core-label">Published in issue</b>: November 5, 2020</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/coronavirus" alt="View article keyword Coronavirus" data-interactiontype="article_recirculation_click">Coronavirus</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/global-health" alt="View article keyword Global Health" data-interactiontype="article_recirculation_click">Global Health</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/infectious-disease-general" alt="View article keyword Infectious Disease General" data-interactiontype="article_recirculation_click">Infectious Disease General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/influenza" alt="View article keyword Influenza" data-interactiontype="article_recirculation_click">Influenza</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/viral-infections" alt="View article keyword Viral Infections" data-interactiontype="article_recirculation_click">Viral Infections</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">John H.</span> <span property="familyName">Beigel</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-4879-4941" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-4879-4941</a></span>, <span property="author" typeof="Person"><span property="givenName">Kay M.</span> <span property="familyName">Tomashek</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Lori E.</span> <span property="familyName">Dodd</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Aneesh K.</span> <span property="familyName">Mehta</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Barry S.</span> <span property="familyName">Zingman</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Andre C.</span> <span property="familyName">Kalil</span>, <span property="honorificSuffix">M.D., M.P.H.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-6489-6294" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-6489-6294</a></span>, <span property="author" typeof="Person"><span property="givenName">Elizabeth</span> <span property="familyName">Hohmann</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Helen Y.</span> <span property="familyName">Chu</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Annie</span> <span property="familyName">Luetkemeyer</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Susan</span> <span property="familyName">Kline</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Diego</span> <span property="familyName">Lopez de Castilla</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Robert W.</span> <span property="familyName">Finberg</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kerry</span> <span property="familyName">Dierberg</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Victor</span> <span property="familyName">Tapson</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Lanny</span> <span property="familyName">Hsieh</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Thomas F.</span> <span property="familyName">Patterson</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Roger</span> <span property="familyName">Paredes</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Daniel A.</span> <span property="familyName">Sweeney</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">William R.</span> <span property="familyName">Short</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Giota</span> <span property="familyName">Touloumi</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">David Chien</span> <span property="familyName">Lye</span>, <span property="honorificSuffix">M.B., B.S.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-0324-0205" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-0324-0205</a></span>, <span property="author" typeof="Person"><span property="givenName">Norio</span> <span property="familyName">Ohmagari</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Myoung-don</span> <span property="familyName">Oh</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Guillermo M.</span> <span property="familyName">Ruiz-Palacios</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Thomas</span> <span property="familyName">Benfield</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Gerd</span> <span property="familyName">Fätkenheuer</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mark G.</span> <span property="familyName">Kortepeter</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Robert L.</span> <span property="familyName">Atmar</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">C. Buddy</span> <span property="familyName">Creech</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jens</span> <span property="familyName">Lundgren</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Abdel G.</span> <span property="familyName">Babiker</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sarah</span> <span property="familyName">Pett</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">James D.</span> <span property="familyName">Neaton</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Timothy H.</span> <span property="familyName">Burgess</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Tyler</span> <span property="familyName">Bonnett</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Michelle</span> <span property="familyName">Green</span>, <span property="honorificSuffix">M.P.H., M.B.A.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mat</span> <span property="familyName">Makowski</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Anu</span> <span property="familyName">Osinusi</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Seema</span> <span property="familyName">Nayak</span>, <span property="honorificSuffix">M.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">H. Clifford</span> <span property="familyName">Lane</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-9509-1045" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-9509-1045</a></span>, for <span property="author" typeof="Person">the ACTT-1 Study Group Members<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) — all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center–Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health and Hospitals–Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) — both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars–Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) — all in California; University of Minnesota (S.K.) and University of Minnesota School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol and irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases–Tan Tock Seng Hospital–Lee Kong Chian School of Medicine–Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital–University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) — both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Beigel at the National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Ln., Rm. 7E60, MSC 9826, Rockville, MD 20892-9826, or at <a href="mailto:jbeigel@niaid.nih.gov">jbeigel@niaid.nih.gov</a>.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A complete list of members of the ACTT-1 Study Group is provided in the <a href="#ap1">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">5220</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2007764" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="ed2b40e1-9f7c-97be-552e-a27f9096e0e5"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=82566104" style="display:inline-block;">
                <img alt="Article has an altmetric score of 12193" src="https://badges.altmetric.com/?size=320&amp;score=12193&amp;types=mabvrtfd" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=82566104">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_ed2b40e1-9f7c-97be-552e-a27f9096e0e5" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=82566104&amp;tab=news">
          Picked up by <b>687</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=82566104&amp;tab=blogs">
          Blogged by <b>83</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=82566104&amp;tab=policy-documents">
          Referenced in <b>18</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=82566104&amp;tab=twitter">
          Posted by <b>9460</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=82566104&amp;tab=patents">
          Referenced in <b>48</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=82566104&amp;tab=facebook">
          On <b>41</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=82566104&amp;tab=wikipedia">
          Referenced in <b>10</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #D5E8F0;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=82566104&amp;tab=reddit">
          Reddited by <b>20</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #F4006E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=82566104&amp;tab=research-highlights">
          Highlighted by <b>1</b> platforms
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #DEDEDE;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=82566104&amp;tab=qa">
          Mentioned in <b>2</b> Q&amp;A threads
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #94DB5E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=82566104&amp;tab=video">
          On <b>11</b> videos
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=82566104&amp;tab=guidelines">
          Referenced in <b>9</b> clinical guideline sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #70B1FF;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=82566104&amp;tab=bluesky">
          Referenced by <b>3</b> Bluesky users
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>7065</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6530837aaf198-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2007764"> <input type="hidden" name="downloadFileName" value="csp_383_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-19%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2007764%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="5220" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">A Ram Lee, </li><li class="list-inline-item cited-by__entry__author">Hong Ki Min, </li><li class="list-inline-item cited-by__entry__author">Seon-Yeong Lee, </li><li class="list-inline-item cited-by__entry__author">Su Been Jeon, </li><li class="list-inline-item cited-by__entry__author">Chae Rim Lee, </li><li class="list-inline-item cited-by__entry__author">Tae Ho Kim, </li><li class="list-inline-item cited-by__entry__author">Jin Hyung Park, </li><li class="list-inline-item cited-by__entry__author">Mi- La Cho, </li></ul><span class="cited-by__entry__title">Remdesivir alleviates joint damage in collagen-induced arthritis and inhibits inflammatory cell death of RA synovial fibroblasts, </span><span class="cited-by__entry__series-title">Immunology Letters, </span><span class="cited-by__entry__volume"><strong>275</strong>, </span><span class="cited-by__entry__page-range">(107009), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.imlet.2025.107009" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.imlet.2025.107009</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.imlet.2025.107009" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Sára Ferková, </li><li class="list-inline-item cited-by__entry__author">Matthieu Lepage, </li><li class="list-inline-item cited-by__entry__author">Antoine Désilets, </li><li class="list-inline-item cited-by__entry__author">Kevin Assouvie, </li><li class="list-inline-item cited-by__entry__author">Gabriel Lemieux, </li><li class="list-inline-item cited-by__entry__author">Isabelle Brochu, </li><li class="list-inline-item cited-by__entry__author">Ulrike Froehlich, </li><li class="list-inline-item cited-by__entry__author">Alice Gravel-Trudeau, </li><li class="list-inline-item cited-by__entry__author">Jules Vastra, </li><li class="list-inline-item cited-by__entry__author">François Jean, </li><li class="list-inline-item cited-by__entry__author">Philippe Sarret, </li><li class="list-inline-item cited-by__entry__author">Richard Leduc, </li><li class="list-inline-item cited-by__entry__author">Pierre-Luc Boudreault, </li></ul><span class="cited-by__entry__title">Optimizing the pharmacokinetics and selectivity of TMPRSS2 inhibitors, </span><span class="cited-by__entry__series-title">European Journal of Medicinal Chemistry, </span><span class="cited-by__entry__volume"><strong>294</strong>, </span><span class="cited-by__entry__page-range">(117579), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ejmech.2025.117579" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ejmech.2025.117579</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ejmech.2025.117579" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Jingyi Wu, </li><li class="list-inline-item cited-by__entry__author">Ting-Hsu Chen, </li><li class="list-inline-item cited-by__entry__author">Zi-han Shen, </li><li class="list-inline-item cited-by__entry__author">May-Jywan Tsai, </li><li class="list-inline-item cited-by__entry__author">Max K. Leong, </li><li class="list-inline-item cited-by__entry__author">Yan-qiang Huang, </li><li class="list-inline-item cited-by__entry__author">Ching-Feng Weng, </li></ul><span class="cited-by__entry__title">Utilizing natural compounds as ligands to disrupt the binding of SARS-CoV-2 receptor-binding domain to angiotensin-converting enzyme 2, impeding viral infection, </span><span class="cited-by__entry__series-title">Phytochemistry Letters, </span><span class="cited-by__entry__volume"><strong>68</strong>, </span><span class="cited-by__entry__page-range">(102999), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.phytol.2025.102999" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.phytol.2025.102999</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.phytol.2025.102999" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Arnau Antolí, </li><li class="list-inline-item cited-by__entry__author">José Luis Gómez-Vázquez, </li><li class="list-inline-item cited-by__entry__author">Angels Sierra-Fortuny, </li><li class="list-inline-item cited-by__entry__author">Carla Bermudez-Carre, </li><li class="list-inline-item cited-by__entry__author">Mario Framil, </li><li class="list-inline-item cited-by__entry__author">Edgar Creus-Bachiller, </li><li class="list-inline-item cited-by__entry__author">Julen Viana-Errasti, </li><li class="list-inline-item cited-by__entry__author">Paula Rofes, </li><li class="list-inline-item cited-by__entry__author">Gemma Rocamora-Blanch, </li><li class="list-inline-item cited-by__entry__author">Lara Hidalgo-Peña, </li><li class="list-inline-item cited-by__entry__author">Lydia García-Serrano, </li><li class="list-inline-item cited-by__entry__author">Raúl Rigo-Bonnin, </li><li class="list-inline-item cited-by__entry__author">Lidia Feliubadaló, </li><li class="list-inline-item cited-by__entry__author">Jesús del Valle, </li><li class="list-inline-item cited-by__entry__author">Laura Calatayud, </li><li class="list-inline-item cited-by__entry__author">Francisco Morandeira, </li><li class="list-inline-item cited-by__entry__author">Conxi Lázaro, </li><li class="list-inline-item cited-by__entry__author">Xavier Solanich, </li></ul><span class="cited-by__entry__title">Autoantibodies neutralizing type I interferons remain a significant risk factor for critical COVID-19 pneumonia in vaccinated patients, </span><span class="cited-by__entry__series-title">Clinical Immunology, </span><span class="cited-by__entry__volume"><strong>276</strong>, </span><span class="cited-by__entry__page-range">(110491), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.clim.2025.110491" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.clim.2025.110491</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.clim.2025.110491" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">A.S. Aruna, </li><li class="list-inline-item cited-by__entry__author">K.R. Remesh Babu, </li><li class="list-inline-item cited-by__entry__author">K. Deepthi, </li></ul><span class="cited-by__entry__title">Autoencoder-based drug-virus association prediction with reliable negative sample selection: A case study with COVID-19, </span><span class="cited-by__entry__series-title">Biophysical Chemistry, </span><span class="cited-by__entry__volume"><strong>322</strong>, </span><span class="cited-by__entry__page-range">(107434), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.bpc.2025.107434" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.bpc.2025.107434</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.bpc.2025.107434" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Inette van Niekerk, </li><li class="list-inline-item cited-by__entry__author">Monica Panieri, </li><li class="list-inline-item cited-by__entry__author">Talitha Müller, </li><li class="list-inline-item cited-by__entry__author">Lovemore Mapahla, </li><li class="list-inline-item cited-by__entry__author">Sonwabile Dzanibe, </li><li class="list-inline-item cited-by__entry__author">Cascia Day, </li><li class="list-inline-item cited-by__entry__author">Dan J. Stein, </li><li class="list-inline-item cited-by__entry__author">Jonny Peter, </li></ul><span class="cited-by__entry__title">Acute serum protein biomarker profile and prevalence of persistent (&gt;6 months) neuropsychiatric symptoms in a cohort of SARS-CoV-2 PCR positive patients in Cape Town, South Africa, </span><span class="cited-by__entry__series-title">Brain, Behavior, &amp; Immunity - Health, </span><span class="cited-by__entry__volume"><strong>46</strong>, </span><span class="cited-by__entry__page-range">(100990), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.bbih.2025.100990" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.bbih.2025.100990</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.bbih.2025.100990" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">I. Kh. Borukaeva, </li><li class="list-inline-item cited-by__entry__author">Z. Kh. Abazova, </li><li class="list-inline-item cited-by__entry__author">Z. A. Kambachokova, </li><li class="list-inline-item cited-by__entry__author">A. A. Kambachokova, </li><li class="list-inline-item cited-by__entry__author">A. A. Kardanov, </li><li class="list-inline-item cited-by__entry__author">M. S. Djabrailova, </li><li class="list-inline-item cited-by__entry__author">Z. I. Сhanieva, </li><li class="list-inline-item cited-by__entry__author">Kh. Kh. Akhmatov, </li><li class="list-inline-item cited-by__entry__author">M. A. Abdurakhmanov, </li><li class="list-inline-item cited-by__entry__author">Sh. M. Baskariev, </li><li class="list-inline-item cited-by__entry__author">E. B. Mezhikhova, </li><li class="list-inline-item cited-by__entry__author">D. A. Shogenova, </li></ul><span class="cited-by__entry__title">Current Perspective on the Treatment of the Novel Coronavirus Infection COVID-19, </span><span class="cited-by__entry__series-title">Antibiot Khimioter = Antibiotics and Chemotherapy, </span><span class="cited-by__entry__volume"><strong>70</strong>, </span><span class="cited-by__entry__issue">1-2, </span><span class="cited-by__entry__page-range">(88-99), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.37489/0235-2990-2025-70-1-2-88-99" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.37489/0235-2990-2025-70-1-2-88-99</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.37489/0235-2990-2025-70-1-2-88-99" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Katsuhiro Nakagawa, </li><li class="list-inline-item cited-by__entry__author">Shingo Ihara, </li><li class="list-inline-item cited-by__entry__author">Junko Yamaguchi, </li><li class="list-inline-item cited-by__entry__author">Tsukasa Kuwana, </li><li class="list-inline-item cited-by__entry__author">Kosaku Kinoshita, </li></ul><span class="cited-by__entry__title">Steroid Pulse Therapy Leads to Secondary Infections and Poor Outcomes in Patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Intensive Care Units: A Retrospective Cohort Study, </span><span class="cited-by__entry__series-title">Viruses, </span><span class="cited-by__entry__volume"><strong>17</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(822), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/v17060822" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/v17060822</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/v17060822" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yongfang Li, </li><li class="list-inline-item cited-by__entry__author">Shiling Yuan, </li></ul><span class="cited-by__entry__title">The Role of Ribose Modifications on the Structural Stability of Nucleotide Analogues with α-Thiotriphosphate at the Active Site of SARS-CoV-2 RdRp, </span><span class="cited-by__entry__series-title">Journal of Chemical Information and Modeling, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1021/acs.jcim.5c00152" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1021/acs.jcim.5c00152</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1021/acs.jcim.5c00152" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Paul Andrei Negru, </li><li class="list-inline-item cited-by__entry__author">Delia Mirela Tit, </li><li class="list-inline-item cited-by__entry__author">Andrei Flavius Radu, </li><li class="list-inline-item cited-by__entry__author">Gabriela Bungau, </li><li class="list-inline-item cited-by__entry__author">Raluca Anca Corb Aron, </li><li class="list-inline-item cited-by__entry__author">Ruxandra Cristina Marin, </li></ul><span class="cited-by__entry__title">Comparative Pharmacovigilance Analysis of Approved and Repurposed Antivirals for COVID-19: Insights from EudraVigilance Data, </span><span class="cited-by__entry__series-title">Biomedicines, </span><span class="cited-by__entry__volume"><strong>13</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(1387), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/biomedicines13061387" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/biomedicines13061387</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/biomedicines13061387" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-19%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2007764%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2007764" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2007764" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2007764.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2007764_f1.jpg"><img src="/cms/10.1056/NEJMoa2007764/asset/ecb4d94c-8b4d-4431-b1a3-b3f8e6229f2a/assets/images/large/nejmoa2007764_f1.jpg" height="3438" width="2345" aria-labelledby="f1" loading="lazy"></a><figcaption>Enrollment and Randomization.</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2007764_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2007764_f2.jpg"><img src="/cms/10.1056/NEJMoa2007764/asset/da50d7a4-c678-4ea9-b0f1-c954b76ceed0/assets/images/large/nejmoa2007764_f2.jpg" height="3311" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Kaplan–Meier Estimates of Cumulative Recoveries.</div><div class="notes"><div role="doc-footnote">Cumulative recovery estimates are shown in the overall population (Panel A), in patients with a baseline score of 4 on the ordinal scale (not receiving oxygen; Panel B), in those with a baseline score of 5 (receiving oxygen; Panel C), in those with a baseline score of 6 (receiving high-flow oxygen or noninvasive mechanical ventilation; Panel D), and in those with a baseline score of 7 (receiving mechanical ventilation or extracorporeal membrane oxygenation [ECMO]; Panel E).</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2007764_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f3"><figure class="graphic"><a class="open-in-viewer" href="#f3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2007764_f3.jpg"><img src="/cms/10.1056/NEJMoa2007764/asset/90aee155-1834-41ed-8856-6bc971d387f7/assets/images/large/nejmoa2007764_f3.jpg" height="2019" width="2640" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Time to Recovery According to Subgroup.</div><div class="notes"><div role="doc-footnote">The widths of the confidence intervals have not been adjusted for multiplicity and therefore cannot be used to infer treatment effects. Race and ethnic group were reported by the patients.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f3"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2007764_f3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2007764_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2007764/asset/62023f30-231c-4440-ba05-bbd2e6f14308/assets/images/large/nejmoa2007764_t1.jpg" height="1882" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">All<br>(N=1062)</th><th class="txxx-borders">Remdesivir<br> (N=541)</th><th class="txxr-borders">Placebo<br>(N=521)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">58.9±15.0</td><td class="xxxx-borders shading">58.6±14.6</td><td class="xxxr-borders shading">59.2±15.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male sex — no. (%)</td><td class="xxxx-borders">684 (64.4)</td><td class="xxxx-borders">352 (65.1)</td><td class="xxxr-borders">332 (63.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race or ethnic group — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">American Indian or Alaska Native</td><td class="xxxx-borders">7 (0.7)</td><td class="xxxx-borders">4 (0.7)</td><td class="xxxr-borders">3 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Asian</td><td class="xxxx-borders shading">135 (12.7)</td><td class="xxxx-borders shading">79 (14.6)</td><td class="xxxr-borders shading">56 (10.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Black or African American</td><td class="xxxx-borders">226 (21.3)</td><td class="xxxx-borders">109 (20.1)</td><td class="xxxr-borders">117 (22.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">White</td><td class="xxxx-borders shading">566 (53.3)</td><td class="xxxx-borders shading">279 (51.6)</td><td class="xxxr-borders shading">287 (55.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Hispanic or Latino — no. (%)</td><td class="xxxx-borders">250 (23.5)</td><td class="xxxx-borders">134 (24.8)</td><td class="xxxr-borders">116 (22.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median time (IQR) from symptom onset to randomization — days<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">9 (6–12)</td><td class="xxxx-borders shading">9 (6–12)</td><td class="xxxr-borders shading">9 (7–13)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">No. of coexisting conditions — no. /total no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">None</td><td class="xxxx-borders shading">194/1048 (18.5)</td><td class="xxxx-borders shading">97/531 (18.3)</td><td class="xxxr-borders shading">97/517 (18.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">One</td><td class="xxxx-borders">275/1048 (26.2)</td><td class="xxxx-borders">138/531 (26.0)</td><td class="xxxr-borders">137/517 (26.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Two or more</td><td class="xxxx-borders shading">579/1048 (55.2)</td><td class="xxxx-borders shading">296/531 (55.7)</td><td class="xxxr-borders shading">283/517 (54.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Coexisting conditions — no./total no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Type 2 diabetes</td><td class="xxxx-borders shading">322/1051 (30.6)</td><td class="xxxx-borders shading">164/532 (30.8)</td><td class="xxxr-borders shading">158/519 (30.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hypertension</td><td class="xxxx-borders shading">533/1051 (50.7)</td><td class="xxxx-borders shading">269/532 (50.6)</td><td class="xxxr-borders shading">264/519 (50.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Obesity</td><td class="xxxx-borders">476/1049 (45.4)</td><td class="xxxx-borders">242/531 (45.6)</td><td class="xxxr-borders">234/518 (45.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Score on ordinal scale — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">4. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (Covid-19–related or otherwise)</td><td class="xxxx-borders shading">138 (13.0)</td><td class="xxxx-borders shading">75 (13.9)</td><td class="xxxr-borders shading">63 (12.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">5. Hospitalized, requiring supplemental oxygen</td><td class="xxxx-borders">435 (41.0)</td><td class="xxxx-borders">232 (42.9)</td><td class="xxxr-borders">203 (39.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">6. Hospitalized, receiving noninvasive ventilation or high-flow oxygen devices</td><td class="xxxx-borders shading">193 (18.2)</td><td class="xxxx-borders shading">95 (17.6)</td><td class="xxxr-borders shading">98 (18.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">7. Hospitalized, receiving invasive mechanical ventilation or ECMO</td><td class="xxxx-borders">285 (26.8)</td><td class="xxxx-borders">131 (24.2)</td><td class="xxxr-borders">154 (29.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Baseline score missing</td><td class="xbxx-borders shading">11 (1.0)</td><td class="xbxx-borders shading">8 (1.5)</td><td class="xbxr-borders shading">3 (0.6)</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2007764_t1.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2007764_t1.jpg"></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2007764_t1.jpg"><div class="label">*</div></a><div id="core-t1fn1" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2007764_t1.jpg">Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. IQR denotes interquartile range, and ECMO extracorporeal membrane oxygenation. The full table of baseline characteristics is available in the </a><a href="#ap1">Supplementary Appendix</a>.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Race and ethnic group were reported by the patients. The number of patients in other races and ethnic groups are listed in Table S1 in the <a href="#ap1">Supplementary Appendix</a>.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Data on symptom onset were missing for 3 patients; data on coexisting conditions were missing for 11 patients and were incomplete for 3 patients.</div></div></div></figcaption><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2007764_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2007764_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2007764/asset/5951769f-594e-43de-8bd5-c265d24d19d5/assets/images/large/nejmoa2007764_t2.jpg" height="2311" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><td class="txlx-borders">&nbsp;</td><th class="txxx-borders" colspan="2"><span>Overall</span></th><th class="txxr-borders" colspan="8"><span>Ordinal Score at Baseline</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>4</span></th><th class="xxxx-borders" colspan="2"><span>5</span></th><th class="xxxx-borders" colspan="2"><span>6</span></th><th class="xxxr-borders" colspan="2"><span>7</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Remdesivir<br>(N=541)</th><th class="xxxx-borders">Placebo<br>(N=521)</th><th class="xxxx-borders">Remdesivir<br>(N=75)</th><th class="xxxx-borders">Placebo<br>(N=63)</th><th class="xxxx-borders">Remdesivir<br>(N=232)</th><th class="xxxx-borders">Placebo<br>(N=203)</th><th class="xxxx-borders">Remdesivir<br>(N=95)</th><th class="xxxx-borders">Placebo<br>(N=98)</th><th class="xxxx-borders">Remdesivir<br>(N=131)</th><th class="xxxr-borders">Placebo<br>(N=154)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Recovery</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">No. of recoveries</td><td class="xxxx-borders">399</td><td class="xxxx-borders">352</td><td class="xxxx-borders">73</td><td class="xxxx-borders">58</td><td class="xxxx-borders">206</td><td class="xxxx-borders">156</td><td class="xxxx-borders">57</td><td class="xxxx-borders">61</td><td class="xxxx-borders">63</td><td class="xxxr-borders">77</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Median time to recovery (95% CI) — days</td><td class="xxxx-borders shading">10 (9–11)</td><td class="xxxx-borders shading">15 (13–18)</td><td class="xxxx-borders shading">5 (4–6)</td><td class="xxxx-borders shading">6 (4–7)</td><td class="xxxx-borders shading">7 (6–8)</td><td class="xxxx-borders shading">9 (7–10)</td><td class="xxxx-borders shading">15 (10– 27)</td><td class="xxxx-borders shading">20 (14– 26)</td><td class="xxxx-borders shading">29 (24–NE)</td><td class="xxxr-borders shading">28 (24–NE)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Rate ratio (95% CI)<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders" colspan="2">1.29 (1.12–1.49 [P&lt;0.001])</td><td class="xxxx-borders" colspan="2">1.29 (0.91–1.83)</td><td class="xxxx-borders" colspan="2">1.45 (1.18–1.79)</td><td class="xxxx-borders" colspan="2">1.09 (0.76–1.57)</td><td class="xxxr-borders" colspan="2">0.98 (0.70–1.36)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Mortality through day 14<a href="#core-t2fn3" role="doc-noteref">‡</a></b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Hazard ratio for data through day 15 (95% CI)</td><td class="xxxx-borders" colspan="2">0.55 (0.36–0.83)</td><td class="xxxx-borders" colspan="2">0.42 (0.04–4.67)</td><td class="xxxx-borders" colspan="2">0.28 (0.12–0.66)</td><td class="xxxx-borders" colspan="2">0.82 (0.40–1.69)</td><td class="xxxr-borders" colspan="2">0.76 (0.39–1.50)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">No. of deaths by day 15</td><td class="xxxx-borders shading">35</td><td class="xxxx-borders shading">61</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">7</td><td class="xxxx-borders shading">21</td><td class="xxxx-borders shading">13</td><td class="xxxx-borders shading">17</td><td class="xxxx-borders shading">14</td><td class="xxxr-borders shading">21</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Kaplan–Meier estimate of mortality by day 15 — % (95% CI)</td><td class="xxxx-borders">6.7<br>(4.8–9.2)</td><td class="xxxx-borders">11.9<br>(9.4–15.0)</td><td class="xxxx-borders">1.3<br>(0.2–9.1)</td><td class="xxxx-borders">3.2<br>(0.8–12.1)</td><td class="xxxx-borders">3.1<br>(1.5–6.4)</td><td class="xxxx-borders">10.5<br>(7.0–15.7)</td><td class="xxxx-borders">14.2<br>(8.5–23.2)</td><td class="xxxx-borders">17.3<br>(11.2–26.4)</td><td class="xxxx-borders">10.9<br>(6.6–17.6)</td><td class="xxxr-borders">13.8<br>(9.2–20.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Mortality over entire study period<a href="#core-t2fn3" role="doc-noteref">‡</a></b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Hazard ratio (95% CI)</td><td class="xxxx-borders" colspan="2">0.73 (0.52–1.03)</td><td class="xxxx-borders" colspan="2">0.82 (0.17–4.07)</td><td class="xxxx-borders" colspan="2">0.30 (0.14–0.64)</td><td class="xxxx-borders" colspan="2">1.02 (0.54–1.91)</td><td class="xxxr-borders" colspan="2">1.13 (0.67–1.89)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">No. of deaths by day 29</td><td class="xxxx-borders shading">59</td><td class="xxxx-borders shading">77</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">9</td><td class="xxxx-borders shading">25</td><td class="xxxx-borders shading">19</td><td class="xxxx-borders shading">20</td><td class="xxxx-borders shading">28</td><td class="xxxr-borders shading">29</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Kaplan–Meier estimate of mortality by day 29 — % (95% CI)</td><td class="xxxx-borders">11.4<br>(9.0–14.5)</td><td class="xxxx-borders">15.2<br>(12.3–18.6)</td><td class="xxxx-borders">4.1<br>(1.3– 12.1)</td><td class="xxxx-borders">4.8<br>(1.6–14.3)</td><td class="xxxx-borders">4.0<br>(2.1–7.5)</td><td class="xxxx-borders">12.7<br>(8.8–18.3)</td><td class="xxxx-borders">21.2<br>(14.0–31.2)</td><td class="xxxx-borders">20.4<br>(13.7–29.8)</td><td class="xxxx-borders">21.9<br>(15.7–30.1)</td><td class="xxxr-borders">19.3<br>(13.8–26.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Ordinal score at day 15 (±2 days) — no. (%)<a href="#core-t2fn4" role="doc-noteref">§</a></b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">1</td><td class="xxxx-borders">157 (29.0)</td><td class="xxxx-borders">115 (22.1)</td><td class="xxxx-borders">38 (50.7)</td><td class="xxxx-borders">28 (44.4)</td><td class="xxxx-borders">90 (38.8)</td><td class="xxxx-borders">62 (30.5)</td><td class="xxxx-borders">18 (18.9)</td><td class="xxxx-borders">14 (14.3)</td><td class="xxxx-borders">11 (8.4)</td><td class="xxxr-borders">11 (7.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">2</td><td class="xxxx-borders shading">117 (21.6)</td><td class="xxxx-borders shading">102 (19.6)</td><td class="xxxx-borders shading">20 (26.7)</td><td class="xxxx-borders shading">15 (23.8)</td><td class="xxxx-borders shading">70 (30.2)</td><td class="xxxx-borders shading">58 (28.6)</td><td class="xxxx-borders shading">22 (23.2)</td><td class="xxxx-borders shading">19 (19.4)</td><td class="xxxx-borders shading">5 (3.8)</td><td class="xxxr-borders shading">10 (6.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">3</td><td class="xxxx-borders">14 (2.6)</td><td class="xxxx-borders">8 (1.5)</td><td class="xxxx-borders">8 (10.7)</td><td class="xxxx-borders">4 (6.3)</td><td class="xxxx-borders">6 (2.6)</td><td class="xxxx-borders">4 (2.0)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">4</td><td class="xxxx-borders shading">38 (7.0)</td><td class="xxxx-borders shading">33 (6.3)</td><td class="xxxx-borders shading">3 (4.0)</td><td class="xxxx-borders shading">7 (11.1)</td><td class="xxxx-borders shading">17 (7.3)</td><td class="xxxx-borders shading">13 (6.4)</td><td class="xxxx-borders shading">12 (12.6)</td><td class="xxxx-borders shading">4 (4.1)</td><td class="xxxx-borders shading">6 (4.6)</td><td class="xxxr-borders shading">9 (5.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">5</td><td class="xxxx-borders">58 (10.7)</td><td class="xxxx-borders">60 (11.5)</td><td class="xxxx-borders">3 (4.0)</td><td class="xxxx-borders">5 (7.9)</td><td class="xxxx-borders">25 (10.8)</td><td class="xxxx-borders">18 (8.9)</td><td class="xxxx-borders">2 (2.1)</td><td class="xxxx-borders">14 (14.3)</td><td class="xxxx-borders">28 (21.4)</td><td class="xxxr-borders">23 (14.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">6</td><td class="xxxx-borders shading">28 (5.2)</td><td class="xxxx-borders shading">24 (4.6)</td><td class="xxxx-borders shading">1 (1.3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">5 (2.2)</td><td class="xxxx-borders shading">7 (3.4)</td><td class="xxxx-borders shading">12 (12.6)</td><td class="xxxx-borders shading">11 (11.2)</td><td class="xxxx-borders shading">10 (7.6)</td><td class="xxxr-borders shading">6 (3.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">7</td><td class="xxxx-borders">95 (17.6)</td><td class="xxxx-borders">121 (23.2)</td><td class="xxxx-borders">1 (1.3)</td><td class="xxxx-borders">3 (4.8)</td><td class="xxxx-borders">13 (5.6)</td><td class="xxxx-borders">21 (10.3)</td><td class="xxxx-borders">16 (16.8)</td><td class="xxxx-borders">20 (20.4)</td><td class="xxxx-borders">57 (43.5)</td><td class="xxxr-borders">74 (48.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">8</td><td class="xxxx-borders shading">34 (6.3)</td><td class="xxxx-borders shading">58 (11.1)</td><td class="xxxx-borders shading">1 (1.3)</td><td class="xxxx-borders shading">1 (1.6)</td><td class="xxxx-borders shading">6 (2.6)</td><td class="xxxx-borders shading">20 (9.9)</td><td class="xxxx-borders shading">13 (13.7)</td><td class="xxxx-borders shading">16 (16.3)</td><td class="xxxx-borders shading">14 (10.7)</td><td class="xxxr-borders shading">21 (13.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Odds ratio (95% CI)</td><td class="xbxx-borders" colspan="2">1.5 (1.2–1.9)</td><td class="xbxx-borders" colspan="2">1.5 (0.8–2.7)</td><td class="xbxx-borders" colspan="2">1.6 (1.2–2.3)</td><td class="xbxx-borders" colspan="2">1.4 (0.9–2.3)</td><td class="xbxr-borders" colspan="2">1.2 (0.8–1.9)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">P values and confidence intervals have not been adjusted for multiple comparisons. NE denotes not possible to estimate.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">Recovery rate ratios and hazard ratios were calculated from the stratified Cox model; the P value for this ratio was calculated with the stratified log-rank test (overall model stratified by actual disease severity). Recovery rate ratios greater than 1 indicate a benefit with remdesivir; hazard ratios less than 1 indicate a benefit with remdesivir.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">Mortality over the first 14 days includes data from all patients who were still alive through 14 days postenrollment, with data censored on day 15, as if 14 days was the maximum follow-up time. Mortality over the entire study period uses the totality of the study data and censors data from patients who completed follow-up alive at 28 days postenrollment.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">The ordinal score at day 15 is the patient’s worst score on the ordinal scale during the previous day. Four patients died 15 days after randomization and are recorded as having died for the ordinal score at the day 15 outcome but not for the mortality day 15 outcome. Scores on the ordinal scale are as follows: 1, not hospitalized, no limitations of activities; 2, not hospitalized, limitation of activities, home oxygen requirement, or both; 3, hospitalized, not requiring supplemental oxygen and no longer requiring ongoing medical care (used if hospitalization was extended for infection-control reasons); 4, hospitalized, not requiring supplemental oxygen but requiring ongoing medical care (Covid-19–related or other medical conditions); 5, hospitalized, requiring any supplemental oxygen; 6, hospitalized, requiring noninvasive ventilation or use of high-flow oxygen devices; 7, hospitalized, receiving invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); and 8, death. Odds ratios and P values were calculated with the use of a proportional odds model (overall model adjusted for actual disease severity). Odds ratio values greater than 1 indicate a benefit with remdesivir.</div></div></div></figcaption></a><figcaption><div class="caption">Outcomes Overall and According to Score on the Ordinal Scale in the Intention-to-Treat Population.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2007764_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2007764_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2007764/asset/f7563782-e109-4d5f-ab97-73e5d2b31c70/assets/images/large/nejmoa2007764_t3.jpg" height="2150" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><td class="txlx-borders">&nbsp;</td><th class="txxx-borders">Remdesivir<br>(N=541)</th><th class="txxx-borders">Placebo<br>(N=521)</th><th class="txxr-borders">Rate Ratio<br>(95% CI)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Median time to clinical improvement (95% CI) — days</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Improvement of one category on ordinal scale</td><td class="xxxx-borders">7.0 (6.0 to 8.0)</td><td class="xxxx-borders">9.0 (8.0 to 11.0)</td><td class="xxxr-borders">1.23 (1.08 to 1.41)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Improvement of two categories on ordinal scale</td><td class="xxxx-borders shading">11.0 (10.0 to 13.0)</td><td class="xxxx-borders shading">14.0 (13.0 to 15.0)</td><td class="xxxr-borders shading">1.29 (1.12 to 1.48)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Discharge or National Early Warning Score ≤2 for 24 hr<a href="#core-t3fn1" role="doc-noteref">*</a></td><td class="xxxx-borders">8.0 (7.0 to 9.0)</td><td class="xxxx-borders">12.0 (10.0 to 15.0)</td><td class="xxxr-borders">1.27 (1.10 to 1.46)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading"><b>Difference (95% CI)</b></td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Hospitalization</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median duration of initial hospitalization (IQR) — days<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">12 (6 to 28)</td><td class="xxxx-borders shading">17 (8 to 28)</td><td class="xxxr-borders shading">−5.0 (−7.7 to −2.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median duration of initial hospitalization among those who did not die (IQR) — days</td><td class="xxxx-borders">10 (5 to 21)</td><td class="xxxx-borders">14 (7 to 27)</td><td class="xxxr-borders">−4.0 (−6.0 to −2.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Patients rehospitalized — % (95% CI)</td><td class="xxxx-borders shading">5 (3 to 7)</td><td class="xxxx-borders shading">3 (2 to 5)</td><td class="xxxr-borders shading">2 percentage points<br>(0 to 4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Oxygen</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median days receiving oxygen if receiving oxygen at baseline (IQR)</td><td class="xxxx-borders shading">13 (5 to 28)</td><td class="xxxx-borders shading">21 (8 to 28)</td><td class="xxxr-borders shading">−8.0 (−11.8 to −4.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">New use of oxygen</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of patients/total no.</td><td class="xxxx-borders shading">27/75</td><td class="xxxx-borders shading">28/63</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Percent of patients (95% CI)</td><td class="xxxx-borders">36 (26 to 47)</td><td class="xxxx-borders">44 (33 to 57)</td><td class="xxxr-borders">−8 (−24 to 8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Median days receiving oxygen (IQR)</td><td class="xxxx-borders shading">4 (2 to 12)</td><td class="xxxx-borders shading">5.5 (1 to 15)</td><td class="xxxr-borders shading">−1.0 (−7.6 to 5.6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Noninvasive ventilation or high-flow oxygen</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median days of noninvasive ventilation or high-flow oxygen use during study if receiving these interventions at baseline (IQR)</td><td class="xxxx-borders shading">6 (3 to 18)</td><td class="xxxx-borders shading">6 (3 to 16)</td><td class="xxxr-borders shading">0 (−2.6 to 2.6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">New use of new noninvasive ventilation or high-flow oxygen use during the study</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of patients/total no.</td><td class="xxxx-borders shading">52/307</td><td class="xxxx-borders shading">64/266</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Percent of patients (95% CI)</td><td class="xxxx-borders">17 (13 to 22)</td><td class="xxxx-borders">24 (19 to 30)</td><td class="xxxr-borders">−7 (−14 to −1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Median days of use during the study (IQR)</td><td class="xxxx-borders shading">3 (1 to 10.5)</td><td class="xxxx-borders shading">4 (2 to 23.5)</td><td class="xxxr-borders shading">−1.0 (−4.0 to 2.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Mechanical ventilation or ECMO</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median days of mechanical ventilation or ECMO during study if receiving these interventions at baseline (IQR)</td><td class="xxxx-borders shading">17 (9 to 28)</td><td class="xxxx-borders shading">20 (8 to 28)</td><td class="xxxr-borders shading">−3.0 (−9.3 to 3.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">New use of mechanical ventilation or ECMO during study</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of patients/total no.</td><td class="xxxx-borders shading">52/402</td><td class="xxxx-borders shading">82/364</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Percent of patients (95% CI)</td><td class="xxxx-borders">13 (10 to 17)</td><td class="xxxx-borders">23 (19 to 27)</td><td class="xxxr-borders">−10 (−15 to −4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Median days of use during the study (IQR)</td><td class="xbxx-borders shading">21.5 (9 to 28)</td><td class="xbxx-borders shading">23 (12 to 28)</td><td class="xbxr-borders shading">1.0 (−6.0 to 8.0)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">The National Early Warning Score includes six physiological measures; total scores range from 0 to 20, with higher scores indicating greater clinical risk.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">The duration of initial hospitalization for patients who died was imputed as 28 days.</div></div></div></figcaption></a><figcaption><div class="caption">Additional Secondary Outcomes.</div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2007764_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2007764</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. <em>J Clin Med</em> 2020;9(4):E1225-E1225.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3390/jcm9041225" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32344679/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000531821000332" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+COVID-19+pandemic%3A+a+comprehensive+review+of+taxonomy%2C+genetics%2C+epidemiology%2C+diagnosis%2C+treatment%2C+and+control.&amp;publication_year=2020&amp;journal=J+Clin+Med&amp;pages=E1225-E1225&amp;doi=10.3390%2Fjcm9041225&amp;pmid=32344679" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. <em>N Engl J Med</em> 2020;382:1787-1799.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_3_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2007764&amp;key=10.1056%2FNEJMoa2001282&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32187464/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000533411000010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+trial+of+lopinavir%E2%80%93ritonavir+in+adults+hospitalized+with+severe+Covid-19.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=1787-1799&amp;doi=10.1056%2FNEJMoa2001282&amp;pmid=32187464" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. <em>JAMA Netw Open</em> 2020;3(4):e208857-e208857.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamanetworkopen.2020.8857" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32330277/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000529959400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+high+vs+low+doses+of+chloroquine+diphosphate+as+adjunctive+therapy+for+patients+hospitalized+with+severe+acute+respiratory+syndrome+coronavirus+2+%28SARS-CoV-2%29+infection%3A+a+randomized+clinical+trial.&amp;publication_year=2020&amp;journal=JAMA+Netw+Open&amp;pages=e208857-e208857&amp;doi=10.1001%2Fjamanetworkopen.2020.8857&amp;pmid=32330277" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. <em>N Engl J Med</em>.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_5_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2007764&amp;key=10.1056%2FNEJMoa2021436&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000623807600009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dexamethasone+in+hospitalized+patients+with+Covid-19+%E2%80%94+preliminary+report&amp;doi=10.1056%2FNEJMoa2021436" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] receiving invasive mechanical ventilation. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of Covid-19 Therapy (RECOVERY) trial </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. <em>Nat Commun</em> 2020;11:222-222.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41467-019-13940-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31924756/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000551460900006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+therapeutic+efficacy+of+remdesivir+and+combination+lopinavir%2C+ritonavir%2C+and+interferon+beta+against+MERS-CoV.&amp;publication_year=2020&amp;journal=Nat+Commun&amp;pages=222-222&amp;doi=10.1038%2Fs41467-019-13940-6&amp;pmid=31924756" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. <em>mBio</em> 2018;9(2):e00221-18-e00221-18.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/mBio.00221-18" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29511076/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000431279600020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Coronavirus+susceptibility+to+the+antiviral+remdesivir+%28GS-5734%29+is+mediated+by+the+viral+polymerase+and+the+proofreading+exoribonuclease.&amp;publication_year=2018&amp;journal=mBio&amp;pages=e00221-18-e00221-18&amp;doi=10.1128%2FmBio.00221-18&amp;pmid=29511076" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. <em>Antiviral Res</em> 2019;169:104541-104541.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.antiviral.2019.104541" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31233808/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000499934800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Broad+spectrum+antiviral+remdesivir+inhibits+human+endemic+and+zoonotic+deltacoronaviruses+with+a+highly+divergent+RNA+dependent+RNA+polymerase.&amp;publication_year=2019&amp;journal=Antiviral+Res&amp;pages=104541-104541&amp;doi=10.1016%2Fj.antiviral.2019.104541&amp;pmid=31233808" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. <em>Sci Transl Med</em> 2017;9:eaal3653-eaal3653.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/scitranslmed.aal3653" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28659436/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000404239400002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Broad-spectrum+antiviral+GS-5734+inhibits+both+epidemic+and+zoonotic+coronaviruses.&amp;publication_year=2017&amp;journal=Sci+Transl+Med&amp;pages=eaal3653-eaal3653&amp;doi=10.1126%2Fscitranslmed.aal3653&amp;pmid=28659436" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. <em>Cell Res</em> 2020;30:269-271.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41422-020-0282-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32020029/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000511096100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Remdesivir+and+chloroquine+effectively+inhibit+the+recently+emerged+novel+coronavirus+%282019-nCoV%29+in+vitro.&amp;publication_year=2020&amp;journal=Cell+Res&amp;pages=269-271&amp;doi=10.1038%2Fs41422-020-0282-0&amp;pmid=32020029" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">de Wit E, Rasmussen AL, Falzarano D, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. <em>Proc Natl Acad Sci U S A</em> 2013;110:16598-16603.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1073/pnas.1310744110" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24062443/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325395600071" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Middle+East+respiratory+syndrome+coronavirus+%28MERS-CoV%29+causes+transient+lower+respiratory+tract+infection+in+rhesus+macaques.&amp;publication_year=2013&amp;journal=Proc+Natl+Acad+Sci+U+S+A&amp;pages=16598-16603&amp;doi=10.1073%2Fpnas.1310744110&amp;pmid=24062443" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. <em>Proc Natl Acad Sci U S A</em> 2020;117:6771-6776.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1073/pnas.1922083117" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32054787/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000521821800064" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Prophylactic+and+therapeutic+remdesivir+%28GS-5734%29+treatment+in+the+rhesus+macaque+model+of+MERS-CoV+infection.&amp;publication_year=2020&amp;journal=Proc+Natl+Acad+Sci+U+S+A&amp;pages=6771-6776&amp;doi=10.1073%2Fpnas.1922083117&amp;pmid=32054787" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Royal College of Physicians. National Early Warning Score (NEWS) 2. 2017 (<a href="https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2">https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Royal+College+of+Physicians.+National+Early+Warning+Score+%28NEWS%29+2.+2017+%28https%3A%2F%2Fwww.rcplondon.ac.uk%2Fprojects%2Foutputs%2Fnational-early-warning-score-news-2%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">King JC, Beigel JH, Ison MG, et al. Clinical development of therapeutic agents for hospitalized patients with influenza: challenges and innovations. <em>Open Forum Infect Dis</em> 2019;6:ofz137-ofz137.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/ofid/ofz137" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31037242/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000474844200041" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+development+of+therapeutic+agents+for+hospitalized+patients+with+influenza%3A+challenges+and+innovations.&amp;publication_year=2019&amp;journal=Open+Forum+Infect+Dis&amp;pages=ofz137-ofz137&amp;doi=10.1093%2Fofid%2Fofz137&amp;pmid=31037242" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. <em>Lancet</em> 2020;395:1569-1578.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)31022-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32423584/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000536542900023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Remdesivir+in+adults+with+severe+COVID-19%3A+a+randomised%2C+double-blind%2C+placebo-controlled%2C+multicentre+trial.&amp;publication_year=2020&amp;journal=Lancet&amp;pages=1569-1578&amp;doi=10.1016%2FS0140-6736%2820%2931022-9&amp;pmid=32423584" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. <em>JAMA</em> 2020;324:1048-1057.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2020.16349" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32821939/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000581077300019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+remdesivir+vs+standard+care+on+clinical+status+at+11+days+in+patients+with+moderate+COVID-19%3A+a+randomized+clinical+trial.&amp;publication_year=2020&amp;journal=JAMA&amp;pages=1048-1057&amp;doi=10.1001%2Fjama.2020.16349&amp;pmid=32821939" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">The CONSORT Group. 3b. Changes to trial design (<a href="http://www.consort-statement.org/consort-2010">http://www.consort-statement.org/consort-2010</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=The+CONSORT+Group.+3b.+Changes+to+trial+design+%28http%3A%2F%2Fwww.consort-statement.org%2Fconsort-2010%29." target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 10, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2022236" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Remdesivir for the Treatment of Covid-19 — Preliminary Report</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 27, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2018715" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Remdesivir — An Important First Step</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">R. Dolin and M.S. Hirsch</span></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 27, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2015301" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Remdesivir for 5 or 10 Days in Patients with Severe Covid-19</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J.D. Goldman and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 9, 2025</div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Surgery, Orthopedic</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885296/sports-medicine-orthopedic-surgeons-suffolk-county-ny/?query=fjwp&amp;rid=6262">Sports Medicine Orthopedic Surgeons Suffolk County, NY</a></div></div><div class="nejm-widget_item"><div><span> Boston, Massachusetts</span></div><div><span>Primary Care</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890187/primary-care-professional-development-program-physician/?query=fjwp&amp;rid=980">Primary Care Professional Development Program Physician</a></div></div><div class="nejm-widget_item"><div><span> Sacramento, California</span></div><div><span>Neurology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885589/physician-neurology-neuroimmunology/?query=fjwf&amp;rid=845679">Physician - Neurology/Neuroimmunology</a></div></div><div class="nejm-widget_item"><div><span> Hollywood, Florida</span></div><div><span>Gastroenterology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883812/gastroenterology-advanced-endoscopy/?query=fjwf&amp;rid=46462">GASTROENTEROLOGY/ADVANCED ENDOSCOPY</a></div></div><div class="nejm-widget_item"><div><span> Hollywood, Florida</span></div><div><span>ENT / Head &amp; Neck Surgery</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883813/head-and-neck-surgical-oncology/?query=fjwf&amp;rid=46462">HEAD AND NECK SURGICAL ONCOLOGY</a></div></div><div class="nejm-widget_item"><div><span> Philadelphia, Pennsylvania</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886520/tenure-track-faculty-position-in-medicine-junior-rank/?query=fjws&amp;rid=121">Tenure Track Faculty Position in Medicine - Junior Rank</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128743&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Fnotablearticles2024%3Fpromo%3DONFQNAR4%26query%3Dcm-ra%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dna24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2007764&amp;pubId=41289217&amp;placeholderId=101337&amp;productId=1007"><img src="/sda/128743/rightRail--notable24_001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6530837aaf198-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6530837aaf198-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6530837aaf198-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$203199478$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$203199478$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$203199478$--></div></div><div class="mlt-body"><!--?lit$203199478$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm-evidence" href="https://evidence.nejm.org/browse/nejm-article-type/original-article?query=recirc_Semantic" target="_self"><!--?lit$203199478$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$203199478$-->NEJM Evidence</span> <span class="mlt-article-pubdate"><!--?lit$203199478$-->Feb 17, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200203?query=recirc_Semantic" target="_self">Detection of Covid-19 Outbreaks Using Built Environment Testing for SARS-CoV-2</a></div><div class="mlt-article-authors"><!--?lit$203199478$-->M. Fralick and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$203199478$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$203199478$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$203199478$-->Mar 04, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2031994?query=recirc_Semantic" target="_self">Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19</a></div><div class="mlt-article-authors"><!--?lit$203199478$-->A.C. Kalil and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$203199478$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$203199478$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$203199478$-->Feb 25, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2021436?query=recirc_Semantic" target="_self">Dexamethasone in Hospitalized Patients with Covid-19</a></div><div class="mlt-article-authors"><!--?lit$203199478$-->The RECOVERY Collaborative Group</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$203199478$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$203199478$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$203199478$-->Sep 10, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2025179?query=recirc_Semantic" target="_self">Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19</a></div><div class="mlt-article-authors"><!--?lit$203199478$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$203199478$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$203199478$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$203199478$-->Jan 27, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2116846?query=recirc_Semantic" target="_self">Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients</a></div><div class="mlt-article-authors"><!--?lit$203199478$-->R.L. Gottlieb and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2007764?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2007764" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2007764.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2007764"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Remdesivir for the Treatment of Covid-19 — Final Report</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMp2022641" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Community Health Workers and Covid-19 — Addressing Social Determinants of Health in Times of Crisis and Beyond</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2015301" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Remdesivir for 5 or 10 Days in Patients with Severe Covid-19</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2007764_f1.jpg"><img src="/cms/10.1056/NEJMoa2007764/asset/ecb4d94c-8b4d-4431-b1a3-b3f8e6229f2a/assets/images/large/nejmoa2007764_f1.jpg" height="3438" width="2345" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption>Enrollment and Randomization.</figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2007764_f2.jpg"><img src="/cms/10.1056/NEJMoa2007764/asset/da50d7a4-c678-4ea9-b0f1-c954b76ceed0/assets/images/large/nejmoa2007764_f2.jpg" height="3311" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Kaplan–Meier Estimates of Cumulative Recoveries.</div><div class="notes"><div role="doc-footnote">Cumulative recovery estimates are shown in the overall population (Panel A), in patients with a baseline score of 4 on the ordinal scale (not receiving oxygen; Panel B), in those with a baseline score of 5 (receiving oxygen; Panel C), in those with a baseline score of 6 (receiving high-flow oxygen or noninvasive mechanical ventilation; Panel D), and in those with a baseline score of 7 (receiving mechanical ventilation or extracorporeal membrane oxygenation [ECMO]; Panel E).</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f3" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2007764_f3.jpg"><img src="/cms/10.1056/NEJMoa2007764/asset/90aee155-1834-41ed-8856-6bc971d387f7/assets/images/large/nejmoa2007764_f3.jpg" height="2019" width="2640" aria-labelledby="f3" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 3</div><div class="fv__item__description"><figcaption><div class="caption">Time to Recovery According to Subgroup.</div><div class="notes"><div role="doc-footnote">The widths of the confidence intervals have not been adjusted for multiplicity and therefore cannot be used to infer treatment effects. Race and ethnic group were reported by the patients.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Outcomes Overall and According to Score on the Ordinal Scale in the Intention-to-Treat Population.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Additional Secondary Outcomes.</div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/383/19" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 383 No. 19</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Nov 05, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2000962" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Brief Report: Lineage-Independent Tumors in Bilateral Neuroblastoma</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">T.H.H. Coorens and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Nov 05, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2001500" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Screening and Intervention to Prevent Falls and Fractures in Older People</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">S.E. Lamb and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Nov 05, 2020</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2021372" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Colchicine in Patients with Chronic Coronary Disease</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">S.M. Nidorf and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2007764%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2007764&amp;pubId=41289217&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2007764%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2007764&amp;pubId=41289217&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id02770866582784922" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6530837aaf198-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6530837aaf198-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6530837aaf198-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6530837aaf198-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6530837aaf198-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6530837aaf198-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6530837aaf198-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6530837aaf198-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6530837aaf198-SJC"></script>
            
            
            
        
    




<div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div><script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6530837aaf198-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d653082e4ef198',t:'MTc0OTUzMTgyOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d653082e4ef198&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><dkk-dgztnvbihdbd></dkk-dgztnvbihdbd><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2007764?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" data-transactionid="de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" id="captureIFrame_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" target="captureIFrame_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" name="capture_screen"><input id="capture_signIn_js_version_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" name="js_version"><input id="capture_signIn_transactionId_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" data-capturefield="undefined" value="de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" type="hidden" class="capture_transactionId_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" name="capture_transactionId"><input id="capture_signIn_form_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" name="form"><input id="capture_signIn_flow_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" name="flow"><input id="capture_signIn_client_id_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" name="client_id"><input id="capture_signIn_redirect_uri_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" name="redirect_uri"><input id="capture_signIn_response_type_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" name="response_type"><input id="capture_signIn_flow_version_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" name="flow_version"><input id="capture_signIn_settings_version_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" name="settings_version"><input id="capture_signIn_locale_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" name="locale"><input id="capture_signIn_recaptcha_version_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_de28qos62mygtd0osyn1m2hxfnyiccrp8ejrbsxe" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>